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Abstract 
The Relationship between Factor V Leiden Mutation  
and Recurrent Abortion Among Palestinian Pregnant Women 
  In The West Bank  
 
The main objective of this study was to investigate the association between factor V 
Leiden mutation and Recurrent Abortion among Pregnant Women in the palestinian 
community in the West Bank. In order to focus the light on this major health problem and 
to figure out the best solutions to eliminate it from our palestinian community.  
A questionnaire was developed and administered, 104 women were chosen, the case group 
included 54 women with no history of high blood pressure, and a history of recurrent 
pregnancy loss of unknown causes. The control group included 50 healthy women , who 
had 2 or more successful pregnancies, and none of them had a history of fetal loss or 
complicated pregnancy. 
This research was carried out in the Medical Research Center at Al-Quds University, in 
Abu Dies (2007-2008), where Factor V Leiden mutation (FVL) was screened by PCR 
method using the ARMS test technique. Blood samples were collected from participants 
for DNA extraction in association with AL Hiba Center /Ramallah, Holy Family Hospital 
/Beithlehem and Palestinian Medical Relief society Clinic / Jericho. 
  
The percentage of abortions among the participants in the case group was very high 68 % 
while all the pregnancies in the control group ended successfully. The distribution of factor 
V Leiden genotype among the case group was 27.8%   (24.1% heterozygous alleles + 3.7 
% homozygous alleles).While in the control group 22 % were heterozygous mutant ; which 
is statistically not significant (P value 0.324).   
14%  of the OCPs users among the case group were heterozygous for Factor V Leiden, 
while all the OCPs users among the control group were of normal genotype. The 
prevalence of IUFD among the participants was 11.1 % all normal for factor V genotype. 
There was no significance association between IUFD and Factor V Leiden mutation. 
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  First trimester aborters were more prevalent  (98.15%) than second trimester aborters 
(1.85% ) ,the distribution of factor V Leiden mutation among the first trimester aborters 
(28.3 % ) was higher than the second trimester aborters ( 0.0 % ) mutant genotype. 
The percentage of the primary aborters was 59.3 % whereas the secondary aborters        
40.7 %. While the distribution of Factor V Leiden mutation among the secondary aborters 
(31.8% heterozygous alleles) was higher than those among the primary abortion (25 %= 
6.30% homozygous alleles + 18.7 % heterozygous alleles). 
These results indicate that statistically Factor V Leiden has no significant role in recurrent 
abortion. The high prevalence of Factor V Leiden among both the case and the control 
groups suggests that further large future studies on other DNA assays should be done for 
those women suffering from recurrent abortion including the genes encoding the natural 
anticoagulants antithrombin, protein C, and protein S, which results in a loss of 
anticoagulant function. Also the role of placental pathogenic mechanisms requires further 
evaluations.  
More investigations and studies should be done taking into consideration the genotype of 
the women couples in order to predict fetus genotype. 
Finally we recommend that we must focus our efforts on increasing the public awareness 
with regard to recurrent abortion and  the importance of making the histopathology test for 
the abortuses in order to know the possible reason for abortion. The role of placental 
pathogenic mechanisms requires further evaluations.  We should concentrate our efforts on 
the  great role of the medical personnel among our populations in providing the necessary 
clinical care, including early diagnosis, medical consolations and therapy to improve the 
quality of lives of those people who suffered from it. 
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Definitions : 
 
ARMS:    Amplification-refractory mutation system (ARMS) 
Amino Acid: The basic building blocks for proteins in the body. Some Amino acids can be 
made by the body from other substances (nonessential) others are absorbed after ingestion 
of (essential) foods with protein (essential) . 
Annexin V (human placental anticoagulant protein 1): Annexin V is an anionic 
phospholipid (PL)-binding protein, expressed by placental and vascular endothelium. It 
plays a thromboregulatory role at the vascular-blood interface by shielding anionic PL 
from forming a complex with coagulation proteins in the circulation.  
Carrier: An individual who has a recessive, disease-causing gene mutation at a particular 
locus on one chromosome of a pair and a normal allele at that locus on the other 
chromosome; may also refer to an individual with a balanced chromosome rearrangement. 
Chromosome 1 is the largest human non sex chromosome, which spans about 247 million 
nucleotide base pairs, and represents about 8% of the total DNA in human cells. It is 
currently believed to have 3,148 genes and was the last completed chromosome, sequenced 
two decades after the beginning of the Human Genome Project. The number of variations 
of nucleotides (SNP or single nucleotide polymorphism) is about 740,000. 
Coagulation: The process by which blood clots.  
Complete abortion:- the fetus, placenta, and other tissues are passed with bleeding. 
Consanguinity: Genetic relatedness between individuals descended from at least one 
common ancestor.  
Deep Venous Thrombosis (DVT): A clot that forms in the deep veins of the legs.  
DNA: (Deoxy ribo Nucleic Acid) Substance from which the genetic code is made. 
Eclampsia - a severe form of pregnancy-induced hypertension resulting in seizures.  
                                                                     ix                                               
Ectopic pregnancy: an abnormal pregnancy in which the fertilized egg implants outside of 
uterus. About 2 percent of all pregnancies develop outside the uterus.  
Embryo - conceptus between time of fertilization to 10 weeks of gestation. 
Enzymes: Biological catalysts that act to speed up chemical reactions.  
Exon: Coding sequence of DNA present in mature messenger RNA. 
Factor: The enzymes of the coagulation cascade are referred to as clotting factors. 
Fetus: from 10 weeks of gestation till time of birth. 
First trimester: within the first 12 gestational weeks. 
Full term: refers to the end of 36 weeks (nine months) from the first day of the woman's 
last menstrual period — the end of gestation. If a woman gives birth earlier than this, it is 
classed premature birth.  
Gene: The basic unit of heredity, consisting of a segment of DNA arranged in a linear 
manner along a chromosome. A gene codes for a specific proteins or part of functional 
protein leading to a particular characteristic or function. 
Genetic code: Carried on chromosomes, made up of DNA. Humans have 46 
chromosomes. Each chromosome contains many genes which encode various traits. 
Gestational age - time from last menstrual period (LMP) up to present. 
Gravidity (G) - number of times the woman has been pregnant  
Heterozygote: An individual who has two different alleles at a particular locus, where one 
allele is usually normal and the other abnormal. 
Homozygote: An individual who has two identical alleles at a particular locus, one on 
each chromosome of a pair. 
Hemophilia: Term describing the condition in which patients have an abnormal tendency 
to bleed because they are unable to adequately form clots. 
                                                                         x 
Homeostasis: The process by which blood flow is stopped. This is another word to 
describe the processes of clot formation. 
Infarction: Lack of blood supply (and thus oxygen) to an organ or tissue resulting in tissue 
death. 
Infant - time of birth to 1 year of age. 
Intrauterine Fetal Death (IUFD): term for death of the fetus inside the uterus. 
Intrauterine growth restriction (IUGR) - term for slowed growth of the fetus during 
pregnancy. 
Ischemia: Lack of blood supply (and thus oxygen) to an organ or tissue . 
locus: The physical site or location of a specific gene on a chromosome . 
Leiden mutation : A glutamine-for-arginine (R506Q) substitution at factor V residue 506.  
Miscarriage: an early pregnancy loss or spontaneous abortion. 
Missed abortion - the embryo or fetus dies, but is not passed out of the uterus. Sometimes, 
dark brown spotting occurs, but there is no fetal heartbeat or growth. 
Mutation: A genetic term. A mutation is a change in the genetic code from what is 
considered normal. Mutations can occur normally and not all mutations are harmful. 
Myocardial Infarction (MI): This is another term for a heart attack. This occurs when a 
blood vessel (an artery) to the heart is blocked.                                                                                    
Parity (P) - number of pregnancies with a birth beyond 20 weeks GA or an infant 
weighing more than 500 g.                                                                                                         
Placenta - an organ, shaped like a flat cake that only grows during pregnancy and provides 
a metabolic interchange between the fetus and mother. (The fetus takes in oxygen, food, 
and other substances and eliminates carbon dioxide and other wastes.)   
xi 
Placental abruption - early detachment of the placenta from the uterus.                                           
Placenta previa - placenta is attached close to or covering the cervix (opening into the 
uterus).                                                                                                                                                  
Platelets (Plt): Cells in the blood which serve to plug holes in the blood vessel walls and 
assist in forming a clot.                                                                                                           
Polymerase Chain Reaction (PCR): A procedure that produces millions of copies of a 
short segment of DNA through repeated cycles of: 1) Denaturation, 2) Annealing, and 3) 
Elongation.                                                                                                                                
Polymorphism: A genetic term. Polymorphisms are changes in the genetic code (like 
mutations) that occur commonly enough in the population such that they are considered a 
variation on normal. These may be harmful, helpful or neither to the persons who have a 
polymorphism.                                                                                                                          
Postpartum: after delivery.                                                                                                                       
Point mutation: An alteration in DNA sequence caused by a single nucleotide base 
change, insertion, or deletion .                                                                                                     
Preclampsia - a condition characterized by pregnancy-induced high blood pressure, 
protein in the urine, and swelling (edema) due to fluid retention.                                                   
Premature - describes a baby born before 37 weeks of pregnancy.                                                                
Prenatal diagnosis: (synonym: prenatal testing) Testing performed during pregnancy to 
determine if a fetus is affected with a particular disorder.                                                              
Preterm - occurring before 37 weeks of pregnancy.                                                                   
Preterm infant - delivered between 24-37 weeks.                                                                       
Previable infant - delivered prior to 24 weeks.  
xii 
Primary abortion:  the result of the first pregnancy is abortion (no children before).  
Protein: Proteins are essential molecules in the body made up of many amino acids strung 
together. DNA encodes the proteins and the cells can then turn the DNA into RNA and 
ultimately into proteins. Clotting factors are one of many types of proteins.                                 
Recurrent Pregnancy Loss (RPL): Three or more spontaneous fetal losses before the 20 
week of pregnancy 
Restriction site: A sequence of DNA that is recognized by an Endonuclease (a protein that 
cuts DNA) as a site at which the DNA is to be cut.                                                                       
Secondary abortion: Abortion occur subsequent to having children; the result of the first 
pregnancy either normal or cesarean delivery.                                                                   
Second trimester – 12 to22 weeks of gestation. 
Stillbirth is a common term for death of a baby while still in the uterus. It is also called 
intrauterine fetal death or demise.                                                                                                                    
Sub endothelium: contains numerous proteins and other molecules which, when exposed 
to the blood stream, serve to attract platelets and encourage clot formation. 
Term infant - delivered between 37-42 weeks.                                                                 
Third trimester - 22 gestational week to delivery. 
Thrombus: A blood clot. 
Thrombophilia: Another term describing hypercoagulable states. These conditions confer 
an increased risk of forming clots. 
Viability - minimum age for fetus survival, (. third trimester).  
Zygote - from fertilization until second cell division  
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List of abbreviations : 
 
1st trimester First trimester 
2nd trimester Second trimester 
3rd trimester Third trimester 
APC  Activated protein C 
ARMS  Amplification refractory mutation system 
DVT Deep vein thrombosis 
FVL Factor V Leiden mutation 
HRT Hormone replacement therapy 
IUFD Intrauterine Fetal Death  
 IUGR intrauterine growth retardation 
IV Intravenous 
OCPs Oral contraceptive pills 
PCR Polymerase chain reaction  
PE Pulmonary embolus 
PL phospholipid 
R5o6Q A glutamine-for-arginine (R506Q) substitution at factor V residue 506 
RPL  Recurrent pregnancy loss 
TAE  Tris-acetate-EDTA  
TE Tris- EDTA 
VTE  venous thromboembolism 
w/v Weight/ volume 
 
 
 
 
 
xiiii 
1 
 
Chapter One 
Introduction 
Thrombophilia 
Thrombophilia: defined as a predisposition to thrombosis. It is a multifactorial  disorder 
caused by inherited and acquired defects, such as mutations in the genes encoding natural 
anticoagulants including antithrombin, protein C, and protein S, or clotting factors 
prothrombin and factor V (Walker. 2000). Acquired conditions include surgery, long 
distance immobilization, pregnancy, antiphospholipid syndrome, obesity, and use of oral 
contraceptive pills (OCPs) (Bertina et al .1994). 
In recent years, a number of studies concerning the relationship between Recurrent 
Pregnancy Loss (RPL) and thrombophilias have been carried out in many countries around 
the world. Some studies reached conflicting conclusions about the role of Factor V Leiden 
and Recurrent Pregnancy Loss .This may  be due to the fact that the incidence of Factor V 
Leiden Mutation in different populations is affected by racial and ethnic differences in the 
gene frequency (Burchard  et al. 2003 ) .Factor V Leiden( a genetic variant) is found in 
about 5 % of caucasians, while, this variant is rarely found in East Asians and Africans 
(prevalence 1  %) (Ridker et al .1997). Rees et al found that the highest prevalence of the 
factor V Leiden mutation was found in Europeans (4.4%); especially among Greeks (7%) 
(Rees et al .1995).Among the population from Asia Minor the prevalence was (0.6%) 
while  it was absent in Africa (Cleary- Goldman et al .2003). 
According to the National Human Genome Research Institute ( www.http:// genome.gov) 
The use of hormones, such as oral contraceptive pills (OCPs) and hormone replacement 
therapy (HRT), including estrogen and estrogen-like drugs taken after menopause, 
increases the risk of developing Deep Vein Thrombosis (DVT) and Pulmonary Embolism 
(PE) .( www.http:// genome.gov) .Healthy women taking OCPs have a 3-4  increased risk 
of developing a DVT or PE compared with women who do not take OCPs. Women with 
factor V Leiden (FVL)who take OCPs have about a 35-fold increased risk of developing a 
DVT or PE compared with women without factor V Leiden and those who do not take 
OCPs. Women with thrombophilic defects are  at increased risk, not only for pregnancy 
associated thromboembolism, but also for other vascular complications of pregnancy, 
including pre-eclampsia and fetal loss (Walker .2000). 
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1.1  Pregnancy  
Normal pregnancy is associated with major changes in all aspects of haemostasis ;increased 
concentrations of most clotting factors, decreased concentrations of some of the natural 
anticoagulants, and reduced fibrinolytic activity (Christopher et al .1998).Consequently, as 
pregnancy progresses and during the puerperium the overall balance is shifted towards 
apparent hypercoagulability (Clark et al .1998). 
Hypercoagulability appears to be an important feature in the pathogenesis of many of the 
complications of pregnancy including venous thromboembolism (VTE), pre-eclampsia (PE), 
intrauterine growth retardation (IUGR) , and fetal loss (Walker .2000). 
Pregnant women have 2–5-fold higher risk for venous thromboembolism compared to non-
pregnant women (Grandone et a1 .1997) , (Price and Ridker . 1997).The FVL variant allele 
increases the risk for venous thromboembolism during pregnancy 8–10 times, compared to 
non-pregnant women with the wild-type genotype (Price and Ridker .1997). 
Recurrent pregnancy loss (RPL), classically defined as 3 or more spontaneous fetal losses 
before the 20th  week of pregnancy , is a health problem affecting 0.5 %-1.0 % of pregnant 
women (Cooper .1994) .RPL may be compounded by its significance as a symptom of a 
serious medical condition with lifelong implications. Miscarriage is a painful and, 
unfortunately, common event, occurring in about 20 % of all pregnancies, fewer than  50 % 
of these cases have definitive causes (Rees et al .1996 ). 
Both inherited and acquired risk factors may be responsible ,these include parental 
chromosomal abnormalities (2%-3%), uterine abnormalities (10 % -15 %),hormonal 
imbalance (25 %) , and the antiphospholipid antibody syndrome (5 %-10 %) ( Gynecologist 
journal no24,2004).Thrombophilias such as Factor V Leiden mutation may be responsible for 
a large portion (40-60 %) of unexplained multiple miscarriages (Brenner et al.1997). 
1.2  Pregnancy and Maternal Fetal Circulation 
 
Once pregnancy is established, survival of the fetus depends on placental development. 
By the 17th day after fertilization, the fetal blood vessels are functional, and placental 
circulation is established (Cleary – Goldman et al 2003). The human placenta is 
characterized by a dual arterial blood supply; maternal (in the intervillous space) and fetal 
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(in the blood vessels of the cord and villi) (Benirschke. 1998). The fetomaternal circulatory 
system may be compromised by disturbances of haemostasis ; a delicate balance between 
anticoagulant and procoagulant factors is needed to maintain this system (Cleary – 
Goldman et al.2003).Teleologically, it makes sense that the placenta must prevent 
hemorrhage so it is prone to infarction and fibrin deposition (Roberts. 2002) . 
 
Annexin V produced by villous trophoblasts is a potent anticoagulant that has a key role in 
preventing intervillous thrombosis and maintaining the fluidity of the placental circulation, 
annexin V inhibits coagulation by binding to phospholipids, the concentration of maternal 
blood levels of factor VIII, fibrinogen, and other procoagulant proteins increases 
considerably during pregnancy in order to prevent placental hemorrhage (Roberts et al. 
2002). 
 Heritable thrombophilia affects the dual function of the placenta, accordingly, risks 
increased for eclampsia, abruptio placenta, fetal growth restriction, and stillbirth 
(Kupferminc et al. 1999). Another study done by Roberts & coworkers has been 
hypothesized that a hypercoagulable state causes placental microthrombosis which can 
lead to placental infarctions, reduced placental blood flow, and possible fetal death 
(Roberts et al. 2002). The majority of studies on thrombosis and RPL focused on the 
maternal rather than fetal circulatory system (Cleary – Goldman et al .2003). 
 One study  suggested that thrombosis can occur in either maternal or fetal circulation, a 2-
fold increase in factor V Leiden carrier abortuses frequency (8.6%) compared  with (4.2%) 
in unselected pregnant controls was found ( Dizon-Townson et al 1997). They also found a 
10-fold increase in the fetal carrier frequency in placentas with more than 10% placental 
infarction.  In fact the frequency of the factor V Leiden mutation in miscarried fetuses has 
been found to be more than twice that in the general population ( Dizon-Townson et al 
1997) .The fetus can inherit the mutation from either maternal or paternal gene pool, thus it 
appears that the carrier status of the fetus, rather than that of the mother, may be the main 
consideration in fetal loss (Cleary – Goldman et al 2003).In a recent study done by Toth & 
coworkers  they found that abortions in the embryonic phase of fetal development were 
associated with a significantly higher incidence of maternal heterozygosity for FVL (Toth 
et al .2009). 
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Figure 1.1 The Dual Circulation of Placenta. 
 
 
Figure 1.1 the anatomy of the placenta. The fetal circulation is shown on the right-hand 
side, the maternal circulation on the left-hand side, and the placenta in the middle. The 
fetal circulation flows from the umbilical artery through the fetal stem and branch villi to 
villous capillaries. The villi, covered by trophoblasts (green) that express annexin V, are 
bathed in blood from the maternal space (lavender). The maternal space is filled from 
maternal decidual arteries and drains through maternal decidual veins. Maternal blood 
contains relatively high amounts of procoagulant proteins, whereas annexin V on the tips 
of the villi is a potent anticoagulant (Roberts et al .2002). 
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1.3   Recurrent Abortion  
Spontaneous abortion (SAB), or miscarriage, is the term used for a pregnancy that ends on 
its own, within the first 20 weeks of gestation. Most miscarriages occur during the first 13 
weeks of pregnancy. There are different types of miscarriage, different treatments for each, 
and different statistics for what a woman chances are of having one. The most common of 
these are: 
self  when a fertilized egg attaches it happens A blighted ovum occurs: ovumA blighted  - 
to the uterine wall, but the embryo does not develop. Cells develop to form the pregnancy 
sac, but not the embryo itself. A blighted ovum usually occurs within the first trimester 
 .before a woman knows she is pregnant
. but is not passed out of the uterus, the embryo or fetus dies :AbortionMissed -
 .but there is no fetal heartbeat or growth, dark brown spotting occurs, Sometimes
ncy in which the fertilized egg implants outside of the an abnormal pregna :Ectopic –
 . percent of all pregnancies develop outside the uterus2about , uterus
 20 >  is a common term for death of a baby while still in the uterus: BirthStill  -
gestational week and before delivery . It is also called intrauterine fetal death (IUFD) 
(http://www.pregnancy online).  
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1.4 Haemostasis (Coagulation and anticoagulation systems) 
Haemostasis is the body's normal physiological response for the prevention and stopping 
of bleeding/hemorrhage. It results in the blocking of any vascular cut; it ensures blood 
fluidity and blood vessel integrity. Abnormalities in haemostasis can result in bleeding 
(hemorrhage) or blood clots (thrombosis) (http://stago.com). 
Haemostasis consists of primary haemostasis with  local vascular contraction (to reduce 
blood flow to the injury site)& platelet plugs formation ,  secondary haemostasis which 
involves clotting of the plasma that result from interaction between numerous  factors and 
inhibitors of the clotting system, and finally  fibrinolysis which is the  process of removing 
the clot once blood vessel integrity has been restored (http://stago.com). 
1.4.1 Coagulation system: 
 
The intrinsic( contact activation pathway) and the extrinsic pathway consist of a series of 
reactions, in which a zymogene (inactive enzyme precursor) of a serine protease and its 
glycoprotein co-factor are activated to become active enzymes that catalyze the next 
reaction in the cascade, ultimately resulting in cross-linked fibrin. The coagulation factors 
are generally serine proteases (enzymes) with some exceptions; for example, factor VIII 
and factorV are glycoproteins and Factor XIII is a transglutaminase. Serine proteases act 
by cleaving other proteins at specific sites. The coagulation factors circulate as inactive 
zymogens  (Marz et al. 2000).The extrinsic pathway and the intrinsic pathway are activated 
as explained below: 
 
The extrinsic pathway (Tissue factor pathway ) 
 
Following damage to the blood vessel, injuries of the endothelium and the exposure of the 
sub endothelial tissue to the blood stream tissue factor (TF, an integral membrane 
glycoprotein in the adventitia) is released, it comes into contact and forms a complex with 
factorVII. In the presence of calcium, factorVII binds to the extra cellular domain of the 
TF and is activated to factorVIIa (factorVIIa circulates in a higher amount than any other 
activated coagulation factor) this complex (TF-factorVIIa) in turn activates factor IX and 
factorX. FactorVII is itself activated by thrombin, as well as factorXIa, plasmin, factor XII 
and factor Xa. The activation of factor Xa by TF-factorVIIa is almost immediately 
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inhibited by tissue factor pathway inhibitor (TFPI).   With the formation of factor Xa, the 
intrinsic and the extrinsic pathway converge. Together with its co-factor ( factor Va), 
calcium and phospholipids, factor Xa builds up the prothrombinase complex which 
activates prothrombin to thrombin (Marz et al. 2000). Thrombin then by limited proteolysis 
converts soluble fibrinogen into insoluble fibrin. It also activates other components of the 
coagulation cascade, including factorV and factorVII (which activates factor XI which in 
turn activates factor IX), and activates and releases factor VIII from being bound to  von 
willibrand factor (vWF). Factor VIIIa is the co-factor of factor IXa and together they form 
the "tenase" complex which proteolytically converts factorX to factor Xa and so the cycle 
continues. As shown later in figure 1.2 Coagulation cascade 
 
The intrinsic  pathway (Contact Activation pathway) 
 
 The formation of the primary complex on collagen by high molecular weight kininogen 
(HMWK), prekallikrein and factor XII (Hageman factor) . Prekallikrein is converted to 
kallikrein and factor XII becomes factor XIIa. factor XIIa converts factor XI into factor 
XIa. Factor XIa activates factor IX, which with its co-factor (factor VIIIa) form the tenase 
complex which activates factor X to factor Xa. Under physiological conditions factor IX is 
a better substrate for the TF- factor VIIa complex than factor X. This directly couples the 
intrinsic to the extrinsic pathway and explains why bleeding tendency is much more sever 
in factor IX deficiency than in deficiencies of other factors of the extrinsic pathway (Marz 
et al. 2000). 
Thrombin has a large array of functions. Its primary role is the conversion of fibrinogen to 
fibrin, the building block of a haemostatic plug. In addition, it activates Factors VIII and 
factor  V and the inhibitor protein C (in the presence of thrombomodulin), and it activates 
Factor XIII, which forms covalent bonds that crosslink the fibrin polymers that form from 
activated monomers. Following activation by the contact factor or tissue factor pathways 
the coagulation cascade is maintained in a prothrombotic 
. state by the continued activation of factor VIII and factor IX to form the tenase complex, 
until it is down regulated by the anticoagulant pathways (Marz et al. 2000). As shown 
below in figure 1.5 Coagulation cascade 
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Figure 1.2 Coagulation cascade 
 (http://web.indstate.edu/thcme/mwking/blood-coagulation.htm#control) 
 
Figure 1.2 : The coagulation cascades 
 
The intrinsic cascade is initiated when contact is made between blood and exposed 
negatively charged surfaces. The extrinsic pathway is initiated upon vascular injury which 
leads to exposure of tissue factor (TF), a sub endothelial cell-surface glycoprotein that 
binds phospholipid. The green dotted arrow represents a point of cross-over between the 
extrinsic and intrinsic pathways. The two pathways converge at the activation of factor X 
to Xa. Factor Xa has a role in the further activation of factor VII to VIIa as depicted by the 
green arrow. Active factor Xa hydrolyzes and activates prothrombin to thrombin. 
Thrombin can then activate factors XI, VIII and V furthering the cascade. Ultimately the 
role of thrombin is to convert fibrinogen to fibrin and to activate factor XIII to XIIIa. 
Factor XIIIa (also termed transglutaminase) cross-links fibrin polymers solidifying the 
clot. HK = high molecular weight kininogen. PK = prekallikrein. PL = phospholipid. 
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1.4.2 Anticoagulation system (Protein C (PC)anticoagulant pathway): 
 Protein C ( Figure 1.6) is a major physiological anticoagulant. It is a vitamin K-dependent 
serine protease zymogene, mainly synthesized in the liver. It is proteolytically activated on 
the surface of the endothelial cells by thrombomodulin bound thrombin (APC).APC 
provides physiologic antithrombotic activity and exhibits both anti-inflammatory and anti-
apoptotic activities. Activated protein C (APC), in a complex with protein S, inactivates 
procoagulant factors Va and VIIIa by proteolytic cleavage at specific arginine residues. 
This serves to control coagulation and limit the extent of thrombus formation. The specific 
cleavage sites on factorVa occur at arginine residues 506,306,679 while those on 
factorVIIIa are at arginine residues 562,336,740. APC requires calcium, phospholipids and 
Protein S (PS) as cofactors. 
Normally factorVa is inactivated by an initial cleavage of the peptide bond on the carboxyl 
side of arginine 506 followed by a second cleavage at arginine 306. The mutant factorV is 
inactivated by cleavage at arginine 306, but this cleavage is ten fold slower without prior 
cleavage at position 506 which is prevented by the factorV Leiden mutation. Thus the 
factorV Leiden mutation leads to the phenomenon of resistance to the anticoagulant 
activity of APC.  
 
 
Figure 1.3 Protein C (inactivator of coagulation factors Va and VIIIa) 
 (Mosnier et al.2006) 
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The Protein C (PC) anticoagulant pathway represents an important regulator of the blood 
coagulation as shown in Figure 1.4 
 
  
 
 
 
Figure1.4 The Protein C anticoagulant pathway. ( Marz et al. 2000 ) 
 
 
Thrombin escaping from a site of vascular injury binds to its receptor thrombomodulin 
(TM) on the intact cell surface; the endothelial PC receptor (EPCR). Thrombin loses its 
procoagulant properties after binding to(EPCR) and becomes a potent activator of protein 
C. Activated protein C(APC), together with its cofactor, protein S, inactivates factors Va 
and VIII a to provide negative feedback to the generation of thrombin. (APC) functions as 
a circulating anticoagulant, which specifically degrades and inactivates the phospholipid-
bound factors Va and VIIIa. This effectively down-regulates the coagulation cascade and 
limits clot formation to sites of vascular injury. This result in down regulation of the tenase 
complex (factor VIIIa+ factor IX a ) and "prothrombinase" complexes ( Marz et al. 2000 ) 
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The endothelial PC receptor (EPCR) is a transmembrane protein belonging  to the major 
histocompatibility class 1 family  of molecules, it is a recently identified regulatory 
component of the PC anticoagulant pathway it has two functions : 
1- To amplify the conversion of PC to APC by thrombin and thrombomodulin. 
2- To inhibit the anticoagulant activity of APC by shifting the specifity of APC away from 
FVa and FVIIa (Marz et al. 2000). 
In factorVa three peptide bonds located at Arg-306, Arg-506, and Arg679 are sensitive to 
proteolysis by APC. The three cleavage reactions have distinct kinetic properties; and 
dependence on phospholipid, differently stimulated by protein S, and yield FVa-
inactivation intermediates with different FVa activities. The cleavage at Arg-506, which is 
kinetically favored, is not dependent on protein S and yields a (FVa) inactivation 
intermediate with decreased FXa-cofactor activity. The APC-mediated cleavage at Arg-306 
is stimulated by protein S and results in almost complete inactivation of FVa .This loss of 
factorVa activity is partly due to reduced affinity for FXa, but the Arg-306 cleavage also 
leads to dissociation of the A2 domain which is crucial for full loss of function. The 
cleavage at Arg-506 may occur in the absence of phospholipid, whereas the cleavage at 
Arg-306 is more dependent on the presence of phospholipid (Yong-Hui Sun et al.2004). 
1.4.3 Activated protein C resistance: 
 
The concept of resistance to APC was first introduced in 1993 by Dahlbäck and associates 
(Dahlbäck et al .1993). Koster and coworkers  in 1993 reported that this phenotype was a 
risk factor for developing a first Deep Vein thrombosis (DVT). In 1994, Bertina et al, 
reported that >80% of cases with APC resistance were carriers of the same mutation in the 
gene of factor V; a G A transition in position 1691, in Exon 10, that predicts the 
replacement of Arg 506 by Gln in factor V molecule (factor V Leiden) (Bertina et al 1994). 
This mutation slows the inactivation of Factor Va by APC causing a hypercoagulable state. 
The presence of Factor V (Leiden) is the most common cause of inherited thrombophilia, 
accounting for 20% to 50% of cases (Bertina et al 1994). 
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1.5 Factor V (Gene, Protein & Mutation)  
The gene for factor V is located on the long (q) arm of chromosome 1 at position 23. It is 
genomically related to the family of multicopper oxidases, and is homologous to 
coagulation factor VIII. The gene spans 70 kb, consists of 25 exons, and the resulting 
protein has a relative molecular mass of approximately 330000 (330 k Da). 
 
 
 
Figure 1.5 Cytogenetic Location of Factor V is: 1q23. 
 
(ghr.nlm.nih.gov/dynamicImages/chromomap/f5.jpeg) 
 
Factor V gene present in three main forms; normal homozygous gene with both alleles 
normal, heterozygous (one allele normal and the other mutated) and homozygous mutant 
(both alleles mutated). Mutations in this gene may results in different disorders in the 
blood clotting system; some mutations in the FV gene prevent the production of a 
functional factor V protein or decrease the amount of the protein in the bloodstream. When 
present in two copies of the F5 gene, these mutations lead to a rare condition called factor 
V deficiency or Para hemophilia. A reduced amount of functional factor V prevents blood 
from clotting normally; causing episodes of abnormal bleeding that can range from mild to 
severe.  
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1.5.1 Factor V protein: 
 
Factor V official symbol is F5, also known by other names such as: coagulation factor V, 
proaccelerin or labile factor, activated protein c cofactor, coagulation factor V, Jin jiang A2 
domain. Factor V circulates in plasma as a single-chain molecule with a plasma half-life of 
about 12 hours. It is made chiefly by cells in the liver  as a single-chain precursor 
glycoprotein of 2,224 amino acids (aa), consisting of a 28-aa N-terminal signal peptide, 
followed by the 2,196-aa mature protein 330 k Da undergoing extensive posttranslational 
modifications before being secreted into the blood ( Wilson et al .1984).In contrast to most 
other coagulation factors, it is not enzymatically active but functions as a cofactor (Gerry 
et al. 2002). 
Factor V plasma concentration is 20 nmol/L ( 0.007 g/L), it has two forms ; either 
circulating in free form in plasma or present in the -granules of platelets; this form 
accounts for 25% of the total FV content in human blood (Tracy et al. 1982).  During 
coagulation, platelet FV is secreted as a result of platelet activation, yet it is unclear 
whether the presence of FV in platelets is the result of the uptake of exogenous FV from 
the circulation via endocytotic processes by megakaryocytes or whether these cells 
themselves can account for the FV production (Gerry et al. 2002). 
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1.5.2 Factor V Function: 
 
Factor V (FV) is a central regulator of homeostasis, serving both as a critical cofactor for 
the prothrombinase activity of factor Xa and the target for proteolytic inactivation by the 
anticoagulant, activated protein C (APC).Factor V is able to bind to activated platelets and 
is activated by thrombin. On activation, factor V is spliced in two chains (heavy and light 
chain with molecular masses of 110000 and 73000, respectively) noncovalently bound to 
each other by calcium. Factor V is active as a cofactor of the thrombinase complex 
(Hajjar.1994). 
Factor V has procoagulant and anticoagulant action as shown next in figure 1.2 
 
 
 
Figure 1.6 Some Procoagulant and Anticoagulant Actions of Factor V (Hajjar.1994). 
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Procoagulant and Anticoagulant Actions of Factor V  
 
Before activation, factor V is a single-chain polypeptide. On the surface of an activated 
platelet Factor V can serve (with protein S) as a cofactor in the inactivation of factor VIIIa 
by activated protein C (APC) (Dahlbäck et al.1994).Factor V is activated to become a two-
chain polypeptide, factor Va (middle), when its B domain is excised by thrombin (factor 
IIa). On the platelet surface, factor Va enhances the activation of prothrombin (factor II) by 
factor Xa. When thrombin binds to its receptor, thrombomodulin (TM), on the surface of 
endothelial cells, it activates protein C (PC). Factor Va augments this action. The APC 
inactivates factor Va (which becomes factor Vi) in the presence of protein S by cleaving a 
single peptide bond, Arg506-Gly507 (dotted line) in factor Va. Procoagulant and 
anticoagulant actions are indicated by red and green arrows, respectively (Hajjar.1994). 
 
1.5.3 Factor V Leiden: 
A variant of human factor V that causes a hypercoagulability disorder ( Factor V Leiden 
Thrombophilia ) named after the city Leiden (The Netherlands), where it was first 
identified  by Prof R. Bertina and associates (Bertina et al. 1994 ) .                                                                
Factor V Leiden is the most common inherited form of thrombophilia, factor V Leiden 
(factor V R506Q, G1691A) is the most common genetic prothrombotic defect, with an 
overall prevalence of carriers among Caucasians around 5%, It is found in 20% of all 
patients with venous thrombosis, and in up to 50% of patients with thrombophilia 
(Rosendal .2005).  
 
 Factor V Leiden leads to resistance to APC- as the result of the mutation of one of the 
cleavage sites where APC inactivates factor V. Because inactivation of the procoagulant 
mutant factor V occurs less efficiently, ‘factor Va persistence’ leads to an increased risk of 
thrombosis. Factor V Leiden mutation (Arg506Gln) is present in 4 to 10% of people of 
Caucasian origin (Bertina et al. 1994,Rees. 1996). The factor V Leiden mutation induces a 
hypercoagulable state which increases the risk of venous thrombosis seven-fold among 
heterozygous carriers and about eighty-fold among homozygous carriers compared to non-
carriers (Rosendal et al. 1995). It has been suggested that factor V Leiden mutation may be 
associated with negative outcomes of reproduction such as recurrent abortion, pre-
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eclampsia, prematurity and small for- gestational-age neonates (Grandone et al .1997, 
Ridker et al. 1998, Brenner et al .1999). 
Mutation of the gene encoding factor V(The APC resistance phenotype ) is associated with 
a guanine-to-adenine substitution at nucleotide 1691 of the factor V gene. This mutation 
produces a glutamine-for-arginine (R506Q) substitution at factor V residue 506 (factor V 
Leiden) as shown in the Figure1.7. Since this amino acid is normally the cleavage site for 
APC, the mutation prevents efficient inactivation of factor V (Hillarp et al.1996).  
 
Factor V Leiden (R506Q) 
505 506 507 
Arg Arg Gly 
AGG C G A GGA 
 ↓  
AGG C A A GGA 
Arg Gln Gly 
Figure 1.7 The G to A point mutation results in the Arginine at the protein C cleavage 
site being replaced by Glutamine. 
When factor V remains active, it facilitates overproduction of thrombin leading to excess 
fibrin generation and excess clotting .The excessive clotting that occurs in this disorder is 
almost always restricted to the veins, where the clotting may cause a deep vein thrombosis 
(DVT). If the venous clots break off, these clots can travel through the heart to the lung, 
where they block a pulmonary blood vessel and cause a pulmonary embolism.  
 Several mutations at the Arg306 residue in factor V have been described in patients with a 
history of thrombosis. These include replacement of Arg306 with threonine (factor V 
Cambridge) (Williamson  et al.1998) or with glycine (Chan  et al .1998).  Occasionally, 
patients have been described who have heterozygous APC resistance due to the factor V 
Leiden mutation and type I factor V deficiency (Guasch et al. 1997) .The plasma of these 
individuals manifests severe APC resistance in activated partial thromboplastin time 
assays, similar to that seen in patients with homozygous factor V Leiden. These patients 
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appear to be more thrombosis prone than their heterozygous relatives with factor V Leiden 
alone, suggesting that the clinical phenotype is similar to patients who are homozygous for 
factor V Leiden (Khan & Dickerman.2006). 
Women with Factor V Leiden disorder have an increased risk of miscarriage and stillbirth, 
some research suggests that it may also increase the risk of other complications during 
pregnancy, these complications may include pregnancy-induced high blood pressure 
(Preeclampsia), slow fetal growth, and early separation of the placenta from the uterine 
wall (placental abruption) (Kupferminc et al .1999). However, it is important to note that 
most women with the factor V Leiden mutation have normal pregnancies (Kupferminc et 
al .1999). Even among Caucasian populations, the association between the FVL mutation 
and RPL is still controversial (Hashimoto et al .1999). 
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1.5 .4 Diagnosis of inherited thrombophilia  
 
The initial test for resistance to APC was based on the  activated  partial thromboplastin 
time (APTT )  a clotting test measures the time it takes to make a clot, most commonly the 
APTT is performed with and without the addition of exogenous APC and the two clotting 
times expressed as a ratio (Dahlbäck .1995). Since then coagulation-based assays for the 
detection of APC resistance have been described and are commercially available, but the 
APC resistance ratios from some of these assay systems, however, have demonstrated 
overlap between unaffected individuals and individuals heterozygous for factor V Leiden 
(Hillarp. 1996). 
 
DNA based assay 
 
 Unlike coagulation-based assays for APC resistance, DNA-based assays are not affected 
by pregnancy, the therapeutic use of anticoagulants, the use of oral contraceptives, or the 
presence of inhibitors such as lupus anticoagulants (Charles. et al .1998). 
 
Three basic methods of DNA based assay are used: 
 
1-   A PCR-based assay that detects the guanine-to-adenine substitution at nucleotide 1691 
by taking advantage of the loss of an MnlI restriction site in the PCR product if the 
mutation is present (MnlI Restriction Fragment Length Polymorphism (RFLP) (Bertina  et 
al. 1994)..Another approach described by the same group was use of allele-specific 
hybridization (Bertina et al. 1994) 
2- The use of primers that introduce a new restriction site if the mutation is present 
(Beauchamp et al. 1994). 
3- The use of allele-specific primers for PCR amplification (Kirschbaum et al .1995 , 
Bellissimo et al. 1996). 
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1.5.5 Treatment of Thrombophilia (Factor V Leiden): 
Treatment of FVL depends on a variety of conditions; such as whether it is caused by 
inherited or acquired clotting abnormalities. If you have only the abnormal factor V gene 
you do not need treatment unless your blood starts to clot. If you have or have had a blood 
clot and have the abnormal factor V gene, you will be put on anticoagulant therapy for a 
period of time ranging from 3 months to life. The length of time you are on anticoagulants 
depends on several issues such as; how many blood clots you have had, how serious your 
clot was and how many additional risk factors you may have. Protective anticoagulation 
therapy may be needed in times where your risk for developing a clot is greater such as 
pregnancy, surgery, or long plane/car rides. 
 
 Some women with thrombophilia might merit anticoagulant prophylaxis during their 
pregnancy and all or most that have a personal or family history of confirmed venous 
thromboembolism merit active thromboprohylaxis during the puerperium (Walker.2000). 
Anticoagulant medications work by inhibiting or altering steps in the coagulation cascade. 
Medications such as warfarin (Coumadin, coumarins) are available in oral forms, whereas 
heparin and the low-molecular-weight heparins require either  intravenous (IV) or 
subcutaneous (injections below the skin) routes for treatment. 
Because coumarins cross the placenta, they have the potential to cause teratogenicity and 
fetal bleeding and should be avoided during pregnancy, although they can be used 
postpartum (Ginsberg et al .1998), Heparins do not cross the placenta and are safe for the 
fetus (Ginsberg et al .1989). Low molecular weight heparins have logistic advantages over 
unfractionated heparin and appear to be associated with a lower incidence of heparin 
induced Thrombocytopenia and Osteoporosis (Walker .2000). In a review of studies in 
which low molecular weight heparin was used in pregnancy, Sanson et al concluded that 
they are a safe alternative to unfractionated heparin as an anticoagulant during pregnancy 
(Sanson et al .1999). 
Low-Molecular-Weight Heparins: are available as subcutaneous (below the skin) 
injections and have greater activity against factor Xa than thrombin , they have fewer 
bleeding complications that reflect their better bioavailability, longer half  life, dose- 
independent clearance and decreased interference with platelets ( Williams Obstetrics 
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2005).Low-Molecular-Weight Heparins used in serial venograms , were more effective 
than the unfractionated form in reducing thrombus size without increasing mortality or 
major bleeding complications (Williams Obstetrics 2005). 
In the study by Gris et al, the live birth rate was 23 out of 80 women (29 %) in the aspirin 
group versus 69 out of 80 (86 %) in the enoxaparin group in patients with known 
thrombophilic predisposition ( Gris et al .2004). 
 
In another cohort study , patients with hereditary thrombophilia and RPL, 26 of the 37 
pregnancies (70 %) in heparin-treated patients resulted in live births, compared with 21 of 
48 (44 %) in untreated patients (OR 3.03; 95 %-CI: 1.12–8.36).The beneficial effect was 
seen mainly in women with no previous live births (OR 9.75; 95 %-CI: 1.59–52.48) (Carp 
et al .2003). 
 
It seems obvious that heparin is the therapy of choice for prevention of recurrent 
miscarriage in patients with thrombophilia (Steinburg et al. 2009). 
 
Heparin Antidote: For patients that have bleeding problems with heparin or require rapid 
neutralization of the heparin anticoagulation effect, Protamine sulfate is used. This is 
generally used only for severe bleeding (Walker. 2000). 
Screening for factor V Leiden  
Screening for inherited or acquired Thrombophilias is best limited to women with a 
personal or family history of venous thrombosis, early onset or recurrent pre-eclampsia, 
recurrent fetal growth restriction, unexplained fetal loss or stillbirth, and placental 
abruption (Bonnar et al.1999, and Lockwood.1999). 
 
 
 
 
 
 
21 
 
 1.6 Literature Review 
 
Since the turn of the last century, there has been extensive research focusing on both the 
genetic and acquired causes of thrombophilia, with particular focus on clotting events in 
the venous circulation. While there is evidence for adverse outcomes of pregnancy 
associated with thrombophilia, some studies ends with conflicting conclusions about the 
role of Factor V Leiden and Recurrent Pregnancy Loss. 
 
A familial component of venous thrombosis was first recognized in the 1960s when 
reduced levels of  AT were shown to be associated with recurrent thrombosis in a family  
(Egeberg . 1965) .The next step in finding other causes of inherited thrombophilia came 
later with the discovery of protein C deficiency (Griffin et al.1981)  
 
Further confirmation of the multiple genetic factors for increased thrombotic risk came 
with the description of activated protein C-Resistance (APC-R) in 1993, and dramatically 
changed the diagnosis and management of venous thrombotic events. Dahlbäck et al 
described a large family from southern Sweden who demonstrated thrombosis in males and 
females throughout several generations and showed an autosomal dominant pattern of 
inheritance (Dahlbäck et al. 1993). The authors concluded that there was abnormality in 
the protein C/protein S regulatory system.  
Subsequently, this abnormality was identified as a single amino acid substitution in one of 
the substrate proteins  ( Factor V ) for  activated protein C (APC )  . This mutation was 
later characterized by Bertina and colleagues at the University of Leiden (Bertina et al. 
1994). Subsequently as many as 15 % of the population in southern Sweden were 
identified as carriers of the factor V Leiden (FVL) gene (Dahlbäck et al. 1993). 
 
Prevalence of Factor V Leiden in different populations 
 
The prevalence of heterozygosity for the factor V Leiden mutation in Europeans, Israeli, 
Arabs, Canadian and Indian populations, ranges from 1 to 8.5 percent with most European 
studies reporting overall rates between 5 and 8 percent (Khan and Dickerman .2006).The 
prevalence is highest in Greece, Sweden, and Lebanon where it reaches about 15 percent in 
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some areas (Finan et al .2002). On the other hand, the mutation is apparently not present in 
African Blacks, Chinese, or Japanese populations (Ridker et al. 1998). 
The Factor V Leiden Mutation and Recurrent Pregnancy Loss: 
 
Several studies on the relationship between Factor V Leiden and recurrent abortion and 
other pregnancy complications were reported. Ridker published a study of 113 consecutive 
white American women with histories of 3 or more unexplained spontaneous abortions 
(Ridker et al. 1998). Sixteen of 437 (3.7%) women in the control group carried the factor V 
Leiden mutation, and 9 of 113 subjects (8%) tested positive for the mutation. These authors 
concluded that the factor V Leiden mutation may play a role in some cases of unexplained” 
recurrent pregnancy loss. 
 
 In another study  by Souza  et al examined 56 consecutive Brazilian women with 3 or 
more fetal losses, forty-six patients were “primary aborting,”, ten patients were “secondary 
aborting,”. Souza et al 1999.The factor V Leiden mutation was found in 4 of 56 patients 
(7.1%) and in 6 of 384 controls (1.6%). Again, an association between recurrent pregnancy 
loss and the factor V Leiden mutation was noted (Souza et al .1999). 
 
Another investigation among Israeli women with unexplained recurrent abortions was done 
by Brenner et al.(1999)to study the role of three thrombophilic mutation including factor V 
Leiden, a case control study was held, 32% of cases had the mutation compared to 7% of 
controls, and they concluded that there was an association between factor V Leiden 
mutation and recurrent pregnancy loss (Brenner et al. 1999). 
 
A case -control study done by Meinardi et al(1999), evaluated fetal wastage in 228 women 
with the factor V Leiden mutation and in 121 non affected controls, approximately 32% of 
carriers and 22% of non carriers experienced fetal loss, carriers had a 29.4% rate of 
miscarriage, and non carriers had a 17.4% rate, stillbirth rates were similar for both groups, 
(5.7% and 5.0% respectively) (Meinardi et al .1999).  Carriers had a 10.1% risk for 
recurrence, and non carriers had a 4.1% risk. Homozygous patients had a greater risk for 
loss than heterozygous subjects did (Meinardi et al. 1999). 
The association between factor V Leiden mutation and recurrent abortion was also studied 
among the Swedish women by Wramsby et al (2000 ) who examined 84 Swedish women 
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with at least 3consecutive, unexplained miscarriages (Wramsby et al .2000). Thirty-two 
women were secondary aborting, and 52 women were primary aborting. Thirteen of the 84 
patients and 2 of 69 controls tested positive for the factor V Leiden mutation. Twelve 
(27.8%) of the primary-aborting women had the mutation, versus only 1 of the secondary-
aborting women .Approximately 15% of the women with 3 or more miscarriages had the 
factor V Leiden mutation (Wramsby et al .2000). 
 
A high prevalence of the factor V Leiden mutation was found among Lebanese women 
with recurrent idiopathic abortions mutation in a case control study conducted by Finan 
and coworkers, Factor V Leiden mutation was found among 41% of cases and among 16% 
of the control group. About 15.6% of the carrier cases were homozygous for the mutation 
and 84.4% were heterozygous, while all the carriers among the control group were 
heterozygous (Finan et al .2002).  
 
Similar results were reported by Mahjoub et al who conducted a control case study among 
the Tunisian women to determine the prevalence of factor V Leiden mutation among 
women with 3 or more consecutive early, late and early and late recurrent abortions, these 
authors found that the prevalence was 27% of the Leiden mutation in the case group 
compared to 11.5% in the control group (Mahjoub et al .2005). Further more a study held 
by Martinelli et al. in Italy  found that both factor V Leiden and the 20210G-A 
prothrombin mutation were associated with an approximate tripling of the risk of late fetal 
loss, approximately 10% of persons carrying the factor V Leiden mutation experience 
clinically significant thrombosis in their lifetime (Martinelli et al. 2000). 
 
Moreover a case control study was carried to find the relation between factor V Leiden and 
venous thromboembolism by Gerhardt et al, in this study the authors examined 119 women 
with a history of venous thromboembolism during pregnancy and the puerperium and 233 
age-matched normal women (Gerhardt et al. 2000). Among the women with a history of 
venous thromboembolism, a prevalence of factor V Leiden was 43.7%, as compared with 
7.7% among the normal women (relative risk of venous thromboembolism, was 9.3) 
(Gerhardt et al .2000). 
  
Other studies were conducted to investigate whether Factor V Leiden is more related with 
the first trimester  or the second trimester abortion, Rai et al published a study that 
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associated APC resistance with second-trimester miscarriage, one hundred twenty English 
women with histories of recurrent abortions and no histories of thromboembolism were 
screened for APC resistance ( Rai et al .1996 ). Seventy women had experienced only first 
trimester losses, and 50 women had experienced both first and second-trimester losses. The 
prevalence of APC resistance was higher in women with second-trimester miscarriages 
(10/50 -  20%) than women with first-trimester losses (4/70 -5.7%). The authors concluded 
that APC resistance may be responsible for second-trimester pregnancy loss (Rai et al 
.1996). 
 
Similar results were found in another study conducted by Younis et al among Israeli 
women and showed that 6 % of the women with the recurrent first trimester abortion have 
the mutation compared with 22 % of women who had abortions in the second trimester. 
(Younis et al .2000). On the contrary Balasch et al did not find such association in a case 
control study included Spanish women with recurrent first trimester abortion and women 
with uncomplicated pregnancies, where the mutation was found in only one case and one 
control (Balasch et al. 1997). 
 
 Many other studies  proved that obstetrical complications such as severe Preeclampsia, 
abruptio placentae, fetal growth retardation, and stillbirth are associated with intervillous 
or spiral-artery thrombosis and inadequate placental perfusion .In these studies was found a 
good relation between Factor V Leiden and these obstetrical complications such as the one 
held by Kupferminc et al in which they investigated 110 women who had 1 of these 
obstetrical complications and 110 women who had one or more normal pregnancies to 
determine the frequency of thrombophilic mutations, the R506Q mutation of factor V was 
detected in 22 of the women with obstetrical complications and in 7 of the women with 
normal pregnancies ( Kupferminc et al. 1999). 
 Based on these findings the idea of general screening pregnant women for thrombophilia 
arose, however one study held by Greer stated that there is no evidence to support general 
screening of pregnant women for Thrombophilia (Greer .2000). Although, all pregnant 
women with a personal or family history of venous thromboembolism should be screened, 
screening should be extended to women with history of second-trimester pregnancy loss, 
severe or recurrent Preeclampsia, or intrauterine growth restriction, though the screening 
policy in a given country should be based on that country's own population data.   
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However, other studies suggested that because of the high prevalence of this mutation in 
certain populations positive effects associated with factor V Leiden have been postulated, 
possibly through human reproduction (Pauer et al. 2003; Hundsdoerfer et al., 2003; 
Morrison et al., 2002; Rai et al., 2001).  Women who carry the factor V Leiden mutation 
lose less blood in menstruation; have higher hemoglobin levels, and possibly a lower 
incidence of life threatening post-partum hemorrhage which could be an evolutionary 
advantage (Lindqvist et al. 2001). 
 
 Surprisingly one study showed higher than expected prevalence of factor V Leiden 
mutation carriers was found in healthy pregnant women (9.2%) compared to general 
population figures (3%) (De Groot et al.1999+ Rosendaal et al.1995).A similar finding was 
reported in a recurrent miscarriage study where the prevalence of factor V Leiden was 
higher in women without a history of recurrent miscarriages (14 %) compared to those 
with recurrent miscarriages (1.7 %); (Dilley et al, 2002).  
 
In an abstract reported by Roque et al, those investigators tested 377 patients with histories 
of recurrent first-trimester pregnancy loss for antiphospholipid antibodies, factor V Leiden 
mutation, prothrombin G20210A mutation, hyperhomocysteinemia, protein C deficiency, 
protein S deficiency, and antithrombin. These authors found no association between 
recurrent fetal wastage and thrombophilia (Roque et al. 2004) .Similar results were found 
by Dizon-Townson group in which they studied 40 couples with 3 or more idiopathic 
pregnancy losses ,the results indicated that none of the 40 women with idiopathic recurrent 
miscarriage tested positive for the factor V Leiden mutation (Dizon-Townson et al .1997).   
 
Furthermore a study held by Kutteh et al, those investigators evaluated 50 white women 
living in Tennessee who had had 3 or more pregnancy losses. One of the patients and 2 of 
the controls were heterozygous for the factor V Leiden mutation, the authors concluded 
that factor V Leiden mutation is not found at an increased frequency in women with 
recurrent early pregnancy losses (Kutteh et al .1999 ) . 
 
 
In the Japanese population, a study was held by Hashimoto et al in which they studied 52 
healthy Japanese women with histories of 3 or more consecutive unexplained first trimester 
miscarriages and 41 of their male partners. The results found none of the 52 women or the 
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41 partners carried the mutation. The control group had similar results. These authors 
concluded that factor V Leiden mutation is not associated with recurrent pregnancy loss in 
the Japanese population (Hashimoto et al .1999). 
 
In a recent study done by Altintas  and coworkers   in south east Turkey, the prevalence of 
FV-Leiden mutation was 7.9% (9/114) in patient group, compared with 7% (13/185) in 
control group (p=0.780), one hundred and two patients were primary and 12 were 
secondary aborters, all FV-Leiden positive cases were primary aborters (8.8% ; 9/102, 
p=0.584).Authors reported that these results suggest that mutations have no role in etiology 
of first-trimester recurrent abortions (Altintas et al .2007)  
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Hypothesis 
 
 Although the Palestinian population is characterized by high fertility rate, it suffers from 
high rate of fetal loss due to many reasons. The high rate of fetal loss makes it necessary to 
investigate the different causes; so as to offer the best solutions and to overcome this 
problem . Eventually this will help to provide protective treatment and better observation 
of women at risk of this medical problem. 
 
Objective 
 
The main objective of this study was to determine  the correlation  between factor V 
Leiden mutation and Recurrent Abortion among Palestinian Pregnant Women  In the west 
bank.  
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Chapter Two 
 
Methodology 
 
2.1 Data Collection 
A retrospective case-control study was conducted among women with recurrent abortion     
(recurrent fetal losses in the three trimesters), especially designed questionnaire was 
developed to collect comprehensive clinical and personal information from all participating 
subjects.  
Direct interview was used to collect data from cases and control groups. The questionnaire 
has been adopted from Shelbayeh work from An-Najah  National University 
(Shelbayeh.2007).The questionnaire contained required information  from all participants 
including: date of birth, age at marriage, result of the first pregnancy, gravidity, number of 
pregnancy losses, types of loss, medical history of the participants, use of drugs, if they 
have any pregnancy problems such as stillbirth or intra uterine fetal death (IUFD), intra 
uterine growth  retardation (IUGR), babies born with low weight and whether they have  a 
family history   ( including mother or sister) who suffered from recurrent abortion or other  
pregnancy complications ( questionnaire form is shown later in the appendices) 
2.1.1 Exclusion criteria: 
- Women who are known to have chronic hypertension or diabetes . 
- Women with anatomical abnormalities of the uterus. 
- Women who are with known causes for recurrent miscarriages  
2.1.2 Inclusion criteria: 
Pregnancy losses were classified into three categories: 
1-First trimester abortion ( 1st trimester) : pregnancy loss within the first 12 gestational 
weeks.                                                                                                                                                    
2- Second trimester abortion(2nd trimester): pregnancy loss between the 12th and the 22nd 
gestational week. 
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3-Third trimester pregnancy loss ( IUFD ): Fetal loss after the 22nd gestational week and is 
considered as Intrauterine Fetal Death (IUFD).  
 Women who had three or more of pregnancy losses (abortion) of unknown causes with 
normal blood pressure and no other health complication were included according to the 
following criteria :  
1- Three or more first trimester abortions.  
2-  Two or more second trimester abortions  
3- One or more third trimester pregnancy loss ( IUFD ).  
The control group includes women who had two or more successful pregnancies with no 
health problems 
2.1.3 Research Place: 
The research was carried out in the Medical Research Centre at Al-Quds University, Abu 
Dies. 
2.1.4 Ethical consideration: 
The study was conducted in accordance with the Helsinki declaration, and approved by the 
Research and Ethical Committee at Alquds University.  
 
2.2 Sample processing: Blood sample collection 
 
Five ml venous blood specimens were collected from each participant into EDTA tubes 
from three centers : 
- AL Hiba Center /Ramallah. 
- Holy Family Hospital / Beithlehem  
- Palestinian Medical Relief society Clinic / Jericho. 
 
All samples were transported on ice to the Medical Research Centre, Al-Quds  
University ,for processing. 
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2.2.1 Genomic DNA Purification: 
 
Genomic DNA was extracted using the Epicenter DNA purification Kit ( the Master Pure 
TM Genomic DNA Purification Kit) according to the protocol described by the 
manufacturer ; as follows : 
1-  Five ml of blood were drawn into an EDTA tube. 
2-  Tubes were centrifuged at 1,000 x g for 15 minutes. 
3-  300 ul of the Buffy coat were transferred to a 1.5 ml microcentrifuge tubes (eppendorf 
tubes), followed by vortexing. 
4-  1.2 ml Lysis buffer 1(10mMTris-HCl,400 mM NACL and 2mM NA2EDTA,pH 8.2) 
were added , tubes were inverted 3 times to mix , the bottom of the tubes were flicked to 
suspend any remaining material. 
5-  Tubes were incubated at room temperature for 5 minutes, and inverted 3 times to mix 
and flicked at the bottom then incubated for an additional 5 minutes , at the end of the 
second incubation ,tubes were inverted 3 times to mix and then were flicked at the bottom 
6-  Tubes were centrifuged for 25 seconds at 10,000 x g . 
7-  Most of the supernatant were removed, leaving approximately 25 ul of liquid; tubes 
were mixed to suspend the pellet (containing white blood cells). 
8-  600ul of Lysis buffer 2 ( 10%SDS, protease K solution [1mg protease K in 1 % SDS 
and mM Na2EDTA] were added, then the cells were pippetted up and down 5-7 times, 
250 ul of the Precipitation Solution (6M NaCl) were added. to the mixture, the tubes were 
mixed vigorously by vortexing for > 30 seconds, followed by centrifugation for 10 minutes 
at 10,000 x g. 
9-  The supernatants were decanted into a clean microfuge tube, 700 ul of ice-cold 
isoprpanol were added. The tubes were inverted several times (30-40) times, stringy  
precipitates were seen. 
10- Tubes were centrifuged at 4° C for 10 minutes at 10,000 x g.. 
11-  The supernatants were carefully discarded without dislodging the pellets, 200 ul of 
Tris-EDTA (TE) Buffer (10mM Tris-HCL, 0.2 mM NA2EDTA, pH7.5) were added. 
12-  The DNA in each tube was suspended by pipetting repeatedly followed by mixing for 
13- seconds, or by incubation for overnight at room temperature. 
14-  Purified DNA was stored at -20° C until used. 
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2.2.2 Genomic DNA Qualification: 
 
Genomic DNA was qualified by running on a 4-mm horizontal 1 % ( w/v) agarose gel 
which was prepared in Tris-acetate-EDTA (TAE )buffer  with the addition of 10 ul of 
10mg/ml Ethedium Bromide . One ul of the extracted genomic DNA was  mixed with     
1.5 ul of 6x Loading buffer (and 9.5 ul)Tris-EDTA (TE) buffer  ( Promega). 
 
A standard 100 bp ladder size marker ( Invitrogen ) was applied to the agarose gel as DNA 
size marker, each gel was allowed to run  at constant voltage of 120 volts , visualized 
under UV light ( Transilluminator UV Sigma 10B201413 ) and photographed using 
Fujifilm/gel documentation system / Ramco company-80-6247-61 / 007-11-0-70. 
 
                                    1         2           3         4           5           6           7 
 
 
 
Figure 2.1 Agarose gel electrophoresis For Genomic DNA ; 
Lanes 1-6 contain separate DNA samples (1 ul) 
 Lane 7 contains 100 Base Pair DNA as size marker ladder 
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2.3 Identification of Mutation 
In order to identify the [R506Q] mutation in Factor V (factor V Leiden), the polymerase 
chain reaction (PCR) method was utilized with the amplification-refractory mutation 
system (ARMS). 
 Using patient genomic DNA as a template, a segment of exon 10 of factor V gene flanking 
nucleotide 1691 was amplified. PCR products were electrophoresed on 1.4 % Agarose gel 
and then visualized after ethedium bromide staining.  
 2.3.1 PCR & ARMS Test: 
ARMS is based on the principle that the (Taq) polymerase enzyme lacks the 3'- 5'  
exonuclease activity and thus a mismatch between the 3'  end of the PCR primer and the  
template will result in greatly reduced amplification efficiency. Hence, the presence of an 
amplified product indicates the presence of a particular allele and visa versa. ARMS test is 
an accurate, rapid and a simple method in which the amplification step and the diagnostic 
steps are combined (Bathelier et al .1998).  
ARMS test is an amplification strategy based on the principle that the allele-specific 
oligonucleotide primers ASP1 and ASP2 are designed to be identical to the sequence of the 
two alleles over a region preceding the position of the variant nucleotide, up to and 
terminating in the variant nucleotide itself. ASP1 will bind perfectly to the complementary 
strand of allele 1 sequence permitting amplification with conserved primer. However, the 
3'-terminal C of the ASP2 primer mismatches with the T of allele 1 sequence, making 
amplification impossible. Similarly ASP2 can bind perfectly to allele 2 and initiate 
amplification, unlike ASP1 . Figure 2.2 illustrates the ARMS test protocol. 
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Figure 2.2 ARMS Test: Correct base-pairing at the 3' end of PCR primers is the basis of 
allele-specific PCR amplification . 
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2.3.2 Primer Sequence:  
 Genomic DNA was utilizes as the template for the PCR/ARMS amplification, one 
reaction with a common normal forward primer  and  a normal reverse primer (C & N) and 
the other with common normal forward primer  and mutant  reverse primers (C &M) as 
shown in table( 2.1) .PCR primers were designed based on Exon 10 sequence of the human 
factor V gene. The  mutant reverse primer  had the 3' terminal nucleotide corresponding to 
the factor V mutation G→ A on the coding strand at position 1691, plus penultimate 
nucleotide mismatch (the mutant primer differs from the normal one at the last two 3' 
bases.) (Bathelier et al .1998)    The primers sequences  used for ARMS were as shown 
below in the table 2.1 
Table (2.1) Primers Sequence 
 
Primer type 
 
 
Sequence 
 
Common  forward normal primer 
sequence    ( C ) ( nucleotide 120 – 140) 
of Exon 10 
 
5'-ACATCTTAGAGTTTGATGA-3' 
 
Normal reverse primer sequence ( N ) 
Correspond to the complementary strand 
of Exon 10 except the penultimate base 
at the 3' end was changed from T to G. 
 
5'- GGACAAAATACCTGTATTCCGC-3' 
 
Mutant reverse primer  sequence ( M )  
 
5'-GGACAAAATACCTGTATTCCCT-3' 
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2.3.3 PCR mixture preparation: 
PCR mixtures were prepared taking into account the number of the samples undergoing the 
reaction. Total volume of the mixture in each PCR tube was 25 ul. 
The PCR mixtures were prepared according to the recipe listed below: 
 
Table (2.2) PCR Mixture content 
 
 
 
Reagents 
 
 
Amount 
10 X TakaRa  buffer 
(final concentration) 
2.5 ul (1X) 
 
TakaRa d NTP mixture (2.5mM each) 
 
2ul 
Forward primer ( 0.15ug/ul) Invitrogen 
 
1ul 
Reverse primer (0 .15ug/ul) Invitrogen 
 
1ul 
Recombinant TakaRa TaqTM DNA 
polymerase(5U/ul) 
 
0.125 ul 
DNA template(0.2ug/ul) 
 
1ul 
 Steril Distilled water(autoclaved) 
 
17.375 
Total Volume 
 
25ul 
 
 
 Two PCR reaction mixtures were prepared, one with Normal primer  pair and the other 
with the mutant reverse primer.  The PCR reactions were done in the Gene Amp® PCR 
thermocycler System 9700( AMIE.#80558120415). 
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Each PCR cycle consisted of 3 steps: 
1- Denaturation step: in which the target DNA is incubated at high temperature       
> 90° C  to separate the two strands and make them accessible to hybridization 
by specific oligonucleotide primers. 
2- Annealing step: in which the reaction mixture is cooled to a specific target 
temperature to allow the primers to anneal to their complementary sequences 
which depends on the primers melting temperature (TM) calculated to be 57° C . 
3- Extension step:   usually at 72 ° C (intermediate temperature) in which the 
primers are extended on the DNA template by the enzyme DNA polymerase.                              
A template, a 220 base pair segment of Exon 10 of the Factor V gene surrounding 
nucleotide 1691 was amplified using the following conditions: 
Initial Denaturation (Hot start) at 95° C for 5 minutes. 
Denaturation at 95° C for 30 seconds. 
Annealing at 57° C for 30 seconds. 
Extension at 72° C for 30 seconds. 
A final extension step at 72° C for 5 minutes. 
 Number of cycles: 30 cycles. 
The PCR products were analyzed by running on 1.4 % Agarose gel and results were 
recorded as Normal, Heterozygous or Mutant. 
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2.3.4 Preparation of PCR products for gel electrophoresis: 
 
1.4 % ( w/v) agarose gel was prepared  in (TAE) buffer , 10 ul of the PCR reaction were 
mixed with 1.5-2 ul of 6x Loading buffer  , the PCR products of each sample were applied 
to the gel in the order that  the upper part of the gel contains the PCR product of normal 
PCR reaction while the lower part of the gel contains the PCR product of the mutant PCR 
reaction . One ul of DNA Ladder was applied to the agarose gel. 
  Each gel was allowed to run at 120 volts and later visualized under UV light                     
( Transilluminator UV Sigma 10B201413 ) and photographed using Fujifilm/gel 
documentation system / Ramco company-80-6247-61 / 007-11-0-70. 
 
All the results were read and recorded for each participant sample as following : 
1- Participants with homozygous normal alleles  yield one band in the normal PCR product 
reaction only  ( upper  part ) 
2- Participants with heterozygous alleles yield two bands ; one in the normal PCR product 
reaction and the other in the mutant PCR product reaction.( upper & lower parts) 
3- Participants with homozygous mutant  alleles  yield  only one band in the mutant PCR 
product reaction  . 
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2.4 Data Analysis  
All the data including clinical informations about the participants and the genetic results of 
factor V gene were collected and analyzed using the SPSS version 12 ( pss.Inc.2003) 
taking into consideration the followings: 
Confidence interval of 95% was calculated in the study, P value of < 0.05 was considered 
for statically significance and the margin error of  5 % was accepted in the study. 
This study provides a descriptive analysis of the main background and independent 
variables, across tabulation analysis to verify the level of statistical significance among 
different dependent and independent variables. 
The following relationships represent the main areas of interest in the analysis and were 
considered in the results and discussion: 
• Distribution of the participants according to the age and to the  Body Mass Index 
(BMI ). 
• Number of pregnancies, deliveries and abortions among the participants. 
• Distribution of different types of the first pregnancy outcomes. 
• Distribution of different types of miscarriages among the case group, according to 
the type and the time of miscarriage. 
• Distribution of factor V Leiden mutation among the participants. 
• Distribution of factor V Leiden mutation among the different pregnancy outcomes 
in the case group in comparison to the control group. 
• Prevalence of Thromboembolic events among relatives of participants. 
• Prevalence of usage of oral contraceptive (OCPs) drugs among participants in the 
study. 
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Chapter Three 
Results  
 
 General characteristics 
Our case- control study included one hundred and four (104) participants; fifty (50) 
controls and fifty four (54) cases. The control group included women who had two or more 
successful pregnancies with no health problems of any sort. The case included women who 
had three or more pregnancy losses (abortion) of unknown causes, however women known 
to have chronic hypertension, anatomical abnormalities of the uterus, known causes for 
recurrent miscarriages and those who are known to have Leiden mutation, were excluded. 
The distribution of the participants as control and case groups is shown below in Figure 3.1  
 
 
 
 
Figure 3.1: Percent distribution of Participants as Control  
and Case groups 
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3.2 Distribution of participants by age 
 
 The mean age of the case group was 30.7 years ( range 19-53 years  ), while the mean age 
of the control group was 32 years ( range 20-47 years) ,as summarized in table 3.2 
 
 
Table 3.2 Distribution of participants by age 
 
Group Mean 
age 
Range 
Case 30.7 19-53 
Control 32 20-47 
 
 
 
3.3 Distribution of participants according to Body Mass Index (BMI):  
 
Figure 3.3 demonstrates the distribution of participants according to BMI where 
18< BMI <25 was considered normal, 25<BMI<30 was considered overweight and 
BMI >30 was considered obese.  
In the control group, 42.7 % ( 21 woman ) were normal  and 57.3% ( 29 woman )were 
overweight or obese, while in the case group 34 % ( 18 woman )  were normal and 66 % 
(35 woman) were overweight or obese .The data indicates that both groups show basically 
similar distribution. 
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Figure 3.3:  Percent distribution of participants according to BMI .  
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Obstetric History 
 
3.4 Number of pregnancies, deliveries and abortions 
 
 Table 3.3 demonstrate that the total number of pregnancies among the case group was 419 
pregnancies, with 285 abortions (68%) and 134 successful deliveries (32%), while the total 
number of pregnancies among the control group was 201 and all were successful. The 
overall percentage of abortion among all the participants was 46%.  
 
 
Table 3.3 Number & Percentage of Pregnancies, Abortions 
 and Deliveries among the participants 
 
  
Number & Percentage 
 Case Control All 
Pregnancies 419 201 620  
Abortions 285  (68%) 0 (0.0%) 285  (46%) 
Deliveries 134  ( 32%) 201 (100%) 335  (54%) 
 
These results are presented next in Figure 3.4 
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 Figure 3.4: Number of Pregnancies, Abortions and  
              Deliveries among all participants 
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3.5 First pregnancy outcome 
Based on the result of the first pregnancy outcomes, this case study group was divided into 
two subgroups: 
- Primary abortion:  The result of the first pregnancy is abortion (no children before).                     
- Secondary abortion: Abortion occurs subsequent to having children; the result of the 
first pregnancy either normal or cesarean delivery. 
Figure 3.5 demonstrates the distribution of different outcomes of the first pregnancy as 
follows:   (37 % ) 20 women in the case group  and  (100% ) 50 women in the control 
group had normal delivery in the first pregnancy , while  3.7% (2 women's  pregnancy) 
ended with cesarean section and 59.3% (32 women's pregnancy) ended with abortions, 
according to these results the percentage of the primary abortion was 59.3 % and that of 
the secondary abortion was 40.7 %.  
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Figure 3.5:  Percent distribution of adverse first pregnancy outcomes . 
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3.6 Distribution of different Types of Miscarriage between Cases  
Four types of miscarriages accounted for all cases , these are illustrated graphically in 
Figure 3.6 as following: 
- Missed abortion:  The highest percentage 63.6% (164 abortion) in which the 
embryo or fetus died but not  passed out of the uterus.  
- Bioclinical type (Bio): 14.7 % ( 38 abortions) in which the pregnancy test give 
positive result while no fetus is growing.              
- A blighted ovum (Bligh): 20.5% (53 abortion), which happens when a fertilized 
egg attaches itself to the uterine wall, but the embryo does not develop.  
- Ectopic (Ecto): 1.2% (3 abortion)  in which the fertilized egg implants outside of 
the uterus. ( these cases were excluded ). 
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Figure 3.6 Percent Distribution of the different Types of Miscarriage among Cases. 
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3.7 Pregnancy Losses 
 Distribution of different pregnancy loss categories  according to  the number of aborters 
and the time of abortion  was as shown in table  3.4  in which 53 women had suffered from 
1st trimester abortion while only 1 woman had suffered from 2nd trimester abortion. Those 
women who had suffered from both types 1st trimester and 2nd trimester ( 12 woman ) were 
categorized according to the number of abortions they had   ; they were assorted as1st 
trimester  whenever the number of abortions in the 1st trimester was higher than in the  2nd 
trimester abortion  and visa versa  . 
 
Table 3.4 Distribution of pregnancy loss categories among the case group 
Group  # of women % of affected women 
  
First trimester 53 98.15  % 
 
Second trimester 1 1.85    % 
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3.8 Participants  Factor V Genotype results 
Participants factor V genotype was determined according to the gel electrophoresis for 
Leiden mutation PCR product analysis in which 220bp band appears in the gel (either in 
the upper or the lower or both ) according to the factor V genotype as illustrated in 
figure3.8.1. 
            1    2    3    4     5   6     7    8     9    10   11  12  13  14  15   16  17  18  19  20 
  
 
Figure 3.8 Gel electrophoresis for Leiden mutation PCR product analysis 
 
PCR reaction products for 18 participants' samples: 
 The upper part includes PCR amplification products with normal primer while the lower 
part shows PCR reaction products with the mutant primer for the same samples.   
Sample # 1: Control PCR reaction (omitting template DNA) to confirm the absence of 
contamination.  
Samples # 7-14and 16 - 18 Amplified products are seen only with the Normal Primer and 
no amplification with the mutant primer indicating Homozygous Normal (both alleles are 
normal) 
Samples # 2, 3, 5, 6, 15, 19;    Amplification bands were detected both with the normal and 
mutant primers indicating heterozygous genotype (one normal and one mutant allele)     
 Sample #   4   : Amplification band is seen only with the mutant PCR primer indicating 
homozygous mutant genotype (both alleles are mutant).  
20: Size marker; DNA ladder (100 base pair ladder).  Sample #    
220 bp 
220 bp 
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3.8.1 Distribution of Factor V mutation among participants : 
According to the results of the gel electrophoresis of the PCR products distribution of 
Factor V genotype among participants was as follows: 
The case group:                                                                                                                                   
1-   Normal alleles: 72.2 % (39 women).                                                                                 
2-   Factor V Leiden mutation  : 27.8 % ( 15 woman)  ; distributed as  24.1%  (13 woman ) 
with heterozygous alleles  and  3.7%  (2 woman) with  homozygous mutant alleles.                           
The control group:                                                                                                                                
1-   Normal alleles: 78% (39 women).                                                                                                       
2- Factor V Leiden mutation: 22 % (11 women) has heterozygous alleles & no 
homozygous alleles (the mutant gene) were found among the control group . 
These  results indicate the prevalence of factor V Leiden was not significantly higher 
among the case group  than the control group ( P value 0.324 )  
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Figure 3.8 .1: Distribution of Factor V Leiden mutation among the participants 
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3.9  Distribution of factor V Leiden mutation among the different categories of 
abortion in comparison with control group. 
First trimester aborters were  more prevalent than second trimester aborters ,based on 
the genetic analysis presented in (Table 3.9 ) factor V Leiden mutation was more 
common among 1st trimester aborters  than other categories. The distribution of  Factor 
V Leiden mutation among  the main aborters  categories was as follows: 
- First trimester abortion  (28.3 %   =24.5% heterozygous genotype and 3.7%  
homozygous mutant genotype ). 
-  Second trimester abortion  was  = 100 % normal factor V genotype and 0.0 % 
factor v Leiden mutation genotype . 
No mutation was detected among women with IUFD. Six women suffered from IUGR, 
but all were genotypically normal for Factor V Leiden mutation.  Some women 
suffered from both types; First trimester and second trimester abortions  (12 women), 
33 % of them   ( 4 woman)  tested positive for Factor V Leiden mutation . ( P value 
0.015 ). 
Table 3.9. Comparison of the distribution of Factor V Leiden mutation between   the 
control group and the case group according to abortion trimester . 
 
Group # of 
women
% of 
affected 
women 
% FVL 
mutation 
p-
value 
Odd 
ratio 
Control group 50 11 22  %    
 
1st trimester 53 15 28.3 % 0.306 1.4 
 
2nd  trimester 1 0 0 % 1.00 0 
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3.10 Prevalence of Thromboembolic events among relatives of participants 
 
By comparing the information in the questionnaire filled by all participants about their 
relatives and their suffering from any kind of thromboembolic events, the results indicate 
that the percentage was significantly higher among the case group (18.5 %)  in comparison 
to the control group   (2 %); ( P Value 0.006, Chi square value 7.490 ) 
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Figure 3.10 Prevalence of Thromboembolic events among relatives of all participants. 
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3.11 Prevalence of usage of oral contraceptive pills (OCPs)  among participants in the 
study  
  
The data indicates that the percentage of usage of the OCP drugs was  slightly higher 
among  cases (12.9%) than among the control group (8%) as shown in figure 3.11     
  These data indicates that the difference  between the two groups is statistically 
insignificant (P value 0.416, chi square value 0.253) 
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Figure 3.11 Prevalence of usage of Oral contraceptive pills ( OCPs) 
 drugs among all participants in the study. 
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Chapter Four  
Conclusion and Recommendations  
  
Giving a live birth is a very valuable event in the women's life; therefore, it is very 
important to avoid abortion which is considered a major problem in the world, the 
incidence of abortion is increasing in most developed and underdeveloped countries; 
occurring in about 20 % of all pregnancies and fewer than 50% of cases has definitive 
causes (Rees et al .1996). Thrombophilia may be a contributing factor in 40-60 % of 
unexplained multiple miscarriages (Brenner et al.1997). Thrombophilia, defined as the 
increased tendency of clot formation, is suggested to be one of the risk factors which 
contribute to the increasing incidence of poor pregnancy outcomes including recurrent 
abortion. (Cooper .1994)  
  
Risk factors associated with thrombophilia are either acquired or inherited (Cooper .1994). 
Acquired factors include smoking, obesity, oral contraceptive pills, sedentary life, 
immobilization (especially in the postoperative period or after long bones fractures), 
pregnancy and other factors (Cooper . 1994). Inherited factors include deficiencies in 
protein S or protein C, mutations in some of the proteolytic cascade proteins, namely 
Factor II, Factor V and Methylene tetrahydrofolate reductase (Cooper .1994). Although a 
clear association has been established between fetal loss and certain thrombophilic states, 
such as antiphospholipid antibody syndromes, antithrombin deficiency, and combined 
defects, reports on the prevalence of inherited prothrombotic defects such as Factor V 
Leiden mutation and Methylene tetrahydrofolate Reductase C677T polymorphism in fetal 
loss are contradictory (Biswas et al .2008) 
 
In the Palestinian community, the incidence of abortion is relatively high; reported to be 4-
8% among women attending UNRWA antenatal care in the northern areas of the West 
Bank (Shelbayeh .2007), it is wroth to mention that this percentage is conservative; it differ 
from one area to another in Palestine (as shown earlier in my results). Therefore, exploring 
the relationship between Thrombophilias and poor pregnancy outcomes represents an 
important task in order to control fetal loss among pregnant Palestinian women.  
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The main aim of this study was to investigate the relationship between Factor V Leiden 
mutation and recurrent abortion among Palestinian women in order to minimize the chance 
of fetal loss through providing the appropriate management to those at high risk. In this 
study, one hundred and eighty (180) women from three medical centers in Ramallah, 
Beithlehem and Jericho were referred to us. From those only one hundred and four women 
were selected and seventy six women were excluded based on a specified inclusion 
criteria. The case group included women who had at least three times abortion with normal 
blood pressure and no other health complication, while the control group included women 
with good health and no pregnancy complications of any type and gave normal birth for at 
least two babies.   
 
Since thrombophilia was suggested to be one of the risk factors that could increase the 
incidence of abortion, our work focused on investigating the contribution of  factor V 
Leiden mutation as an inherited factor for thrombophilia on abortion  .From the acquired 
factors our investigation focused on obesity and oral contraceptive pills. The data collected 
for these two factors indicates that both groups show basically similar distribution. Other 
factors, including smoking were not prevalent among participants in our study group. 
Diagnosing thrombophilia was made using DNA-based assay (ARMS Test). This assay is 
more accurate than coagulation screening test because unlike coagulation screening test, 
DNA-based assays are not affected by pregnancy, therapeutic use of anticoagulants, use of 
oral contraceptives, or the presence of inhibitors such as lupus anticoagulants (Charles et 
al. 1998).Taking into consideration that Factor V Leiden is difficult to study because, 
although the mutation is fairly common in certain populations, it is rare in others,  and 
more important, many affected patients do not have adverse results from the mutation        
(Wramsby et al. 2000).  
The percentage of abortions among the case group was shown to be very high; reaching 
68%, while all pregnancies in the control group ended successfully. The results of first 
pregnancy among the participants showed that all the pregnancies in the control group 
ended by normal vaginal deliveries, while in the case group 37% of first pregnancies  
ended with normal delivery, 3.7% of first pregnancies  ended with cesarean section while 
59.3% of first pregnancies ended with abortions. These results reflect the high incidence of 
abortion among the Palestinian population in comparison to the rate of abortion in 
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developed and underdeveloped countries totaling 20 %, keeping in mind that the 68% is 
among a group who are   already suffering from recurrent pregnancy loss (RPL). 
The prevalence of Factor V Leiden mutation was 27.8 % among the case group                
(24.1 % heterozygous and 3.7 % homozygous) and 22 % among the control group all are 
heterozygous for the mutant allele, this indicates that there is no significant difference in 
the total incidence of the Factor V Leiden mutation between the case and the control group 
(P value 0.324) except for the homozygous alleles in the case group. 
 BMI values showed basically similar distribution between the case and the control group, 
the usage of oral contraceptive pills (OCPs) among the case group (12.9%) was not 
significantly higher than that among the control group (8%) (P value 0.416). Meanwhile 14 
% of the OCPs users among the case group were heterozygous while all the OCPs users 
among the control group were of normal genotype.  
Intra uterine growth retardation (IUGR) was seen only in one woman of the control group 
and six women of the case group all with normal factor V genotype.  Intra uterus fetal 
death (IUFD) was found in 6 women among the case group (11.1 %) with normal factor V 
genotype. No significance association between IUGR and IUFD and Factor V Leiden 
mutation is observed in this study, these results are in agreement with Lindoff et al (1997), 
Lindqvist et al (1998), and Kupferminc et al 1999, who concluded that although Factor V 
Leiden mutation and IUGR has been observed in association with APC resistance and 
Preeclampsia, IUGR prevalence did not correlate with APC resistance. 
Comparing the distribution of the different categories of abortion, first trimester aborters 
was more prevalent than the second trimester aborters ; 53 women were first trimester 
aborters while only one woman was second trimester aborters ,also the prevalence of factor 
V Leiden genotype was more prevalent among the first trimester  abortion  (28.3 %   
=24.5% heterozygous genotype and 3.7%  homozygous mutant genotype) than the second 
trimester ( 0.0 %) only one woman with normal genotype .Keeping in mind that  several 
women have both types first and second trimester abortions. (12 woman 22%; 4 of them 
had Factor V Leiden Mutation 33%). On the contrary other studies, one done by Rai et al 
showed an association between APC resistance and second-trimester miscarriage (Rai et al 
.2000). Similarly ,Younis and coworkers showed that the prevalence of factor V Leiden 
mutation among cases with second trimester was higher than those with first trimester 
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abortion among Israeli women (Younis et al. 2000) .Balasch et al did not found such an 
association in a case control study among Spanish women with recurrent first trimester 
abortion (Balasch et l .1997). 
 Factor V Leiden mutation was more prevalent among secondary abortion (31.8% 
heterozygous) than primary abortion (25 % including 6.3% homozygous and 18.7% 
heterozygous).  The main difference between the case and the control groups regarding 
Factor V Leiden mutation was the homozygous genotype of the mutation being only 
detected among the case group and absent in the control group. Moreover the different 
types of abortion were investigated in association with Factor V Leiden mutation. Most 
women in the case group suffered from more than one type of miscarriages. Some suffered 
from both first and second trimester abortions. Ectopic pregnancy (1.2%) was considered 
as abnormal pregnancy and was excluded from the study. 
The missed type was the highest among first trimester abortion cases, which make sense 
keeping in mind that the first trimester period is very important in the embryo life. 
Definitely once pregnancy is established, survival of the fetus depends on placental 
development which is accomplished by the 17th day after fertilization (Cleary – Goldman 
et al .2003). One study suggested that fetal carriers of the FVL mutation are at high risk 
during prenatal life (Dizon-Townson et al.1997). They explained that the fetomaternal 
circulatory system depends on both the mother and the fetus genotype, and thrombosis can 
occur in either maternal or fetal circulation. They found that the frequency of factor V 
Leiden mutation in miscarried fetuses is more than twice that in the general population 
(Dizon-Townson et al .1997). However, the main part of the placentary perfusion is 
encoded by both the maternal and the paternal genome (Toth et al .2008). 
The fact that a fetus can inherit the mutation from either the maternal or the paternal gene 
pool, makes it obvious that the carrier status of the fetus, rather than that of the mother, 
may be the main consideration in fetal loss (especially with mothers of normal genotype) 
where it may cause thrombosis in the fetal circulation in the placenta (Cleary – Goldman et 
al. 2003). 
A recent study conducted by Rashmi and colleagues  on fetal gene defects  and pregnancy 
failure in factor V Leiden mothers established a cause–effect relationship for the observed 
epidemiologic association between maternal FVL status and fetal loss and identified fetal 
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gene defects as risk modifiers of pregnancy failure in prothrombotic mothers ( Rashmi et 
al.2007).These authors   showed that  pregnancy failure is mediated by Par 4-dependent 
activation of maternal platelets at the fetomaternal interface and likely involves a 
pathogenic pathway independent of occlusive thrombosis ,these results further demonstrate 
that the interaction between two given thrombosis risk factors produces markedly disparate 
consequences on disease manifestation (i.e., thrombosis or pregnancy loss), depending on 
the vascular bed in which this interaction occurs (Rashmi et al. 2007). 
In a parallel  study with similar investigations done in the northern  areas of the West Bank 
, authors reported that the mutation was confirmed in 35 cases out of 137 (25.5%) and in 
13 out of 155 controls (8.4%) (Shelbayeh . 2007). Contrary to our results they found a 
significant association between factor V Leiden and recurrent abortion. Factor V Leiden 
mutation was more prevalent in the second trimester than the first trimester. Table 4.1 
below illustrates the main points of resemblance and differences between the two studies. 
Table 4.1 Comparison between the study done in the northern areas and ours done in 
the central and southern areas of the West Bank 
 Northern areas of West 
Bank 
Central & southern areas of 
west Bank 
Distribution of factor V 
Leiden  
25.5% 27.8% 
Heterozygous Case: 23.3 
Control :8.4% 
Case: 24.1 % 
Control : 22% 
Homozygous Case:2.2 
Control: 0 % 
Case: 3.7% 
Control : 0% 
 
The main resemblance between both studies was the prevalence of the heterozygous 
genotype in both the case group, while the homozygous genotype of the mutation was 
absent among the control group in both studies. In both studies Factor V Leiden was more 
prevalent among Secondary abortion than Primary abortion .It is worth to mention that 
among the group of women excluded from our study (76 women), 2 women were 
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homozygous and 13 were heterozygous. Therefore we suggest that it is important to follow 
up with these women in the future to see the status of their delivery trend. 
 The difference in the sample size due to differences in the inclusion criteria in both studies 
in the northern areas, e.g. pregnancy induced hypertension cases were included while in 
our case control study they were excluded. Still our sample size and negative results are 
comparable to those of the previous studies; the prevalence of FVL mutation in women 
with RSA and in a control group were 0/40 and 0/25 (Dizon-Townson et al.1997) and 
10.7% (9/84) and 9.2% (8/87) (Pauer et al.1998) respectively. 
 A study done by Bettina and coworkers suggested that although recurrent miscarriage was 
not associated with paternal thrombophilia, abortions in the embryonic phase of fetal 
development were associated with a significantly higher incidence of maternal 
heterozygosity for FVL (Bettina Toth et al .2008). 
Comparing our results with those of other studies done in other countries and populations, 
our results are in agreement with studies not supporting the association between Factor V  
Leiden and RPL such as those of Balasch et al among Spanish women in whom the 
mutation was found only in one case and one control (Balasch et al .1997).  Another study 
done among a group of white women from Tennessee- America in which only one of the 
patients and 2 of the controls were heterozygous for the factor V Leiden mutation (Kutteh 
et al .1998). Further more Preston et al failed to establish a significant association between 
Factor V Leiden mutation and RPL among European women participating in the European 
Cohort on Thrombophilia (Cleary- Goldman et al .2003). Table 4.2 summarizes the results 
of these studies. 
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Table 4.2 Studies Not Supporting Association between Factor V Leiden Mutation and 
Recurrent Abortion 
 
 
 
 
 
 
Other studies reported a strong relationship between Factor V Leiden mutation and 
recurrent abortion; these studies are summarized in Table 4.3  
Prevalence Of Factor V 
Leiden Mutation 
 
Author 
 
Target 
Population    Cases        
(Frequency)
Controls 
(Frequency)
 
P-Value 
Odds ratio 
95%Confidence 
interval 
Preston   European     26.9 
(38/141)      
23.5 
(93/395)    
0.04      0.9 (0.5-1.5) 
 
Kutteh American 2.0 (1/50) 4.0 (2/50) 0.49 (0.04-5.58) 
 
Pauer  
 
German  10.7 (9/84)  9.2 (8/87)  …(*)… …(*)… 
Dizon-
Townson  
 
American  0.0 (0/40)  0.0 (0/25)  …(*)… …(*)… 
Balasch 
 
Spanish 
 
1.8 (1/55)  
 
2.0 (1/50)  
 
…(*)… 
 
(0.5-5.5) 
 
Hashimoto 
 
Japanese 
 
0.0 (0/52)  
 
  0.0 (0/55)  
 
...(*)… 
 
… 
 
(Cleary- Goldman et al 2003).(*)- The values were not calculated in the concerned references 
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Table 4.3 Studies supporting the association between the 
Factor V Leiden and Recurrent Abortion 
Prevalence Of Factor V 
Leiden Mutation 
 
Author 
 
Target 
Population    
Cases        
(Frequency)
Controls 
(Frequency)
 
P-
Value 
Odds ratio 
95%Confidence 
interval 
Grandone 
 
Southern 
Italian 
 
16.3 (7/43) 
 
4.2 (5/118) 
. 
 
0.01 
 
4.39 (1.3, 14.7) 
 
Ridker American 8.0 (9/113) 3.7 
(16/437). 
0.05 2.3 (1.0, 5.2) 
Brenner 
 
Israeli 
 
32.0 
(24/76) 
 
10.0 
(11/106) 
 
<0.001 4.0 (1.8, 8.8) 
 
Souza 
 
Brazilian 7.1 (4/56) 
 
1.6 (6/384) 
 
… 
 
4.9 (1.3, 17.8) 
 
Meinardi Scandinavian 31.6 
(72/228)* 
29.4 
(67/228)† 
 
22.3 
(27/121)*  
17.4 
(21/121)† 
0.06 2.12 (1.35, 3.33) 
2.08 (1.33, 3.25) 
Younis 
 
 
Israeli 
 
19.0 
(15/78) 
 
6.0 (8/139) 
 
<0.05 
 
3.17 (1.03, 9.8) 
 
Wramsby 
 
 
Swedish 
 
15.5 
(13/84) 
 
2.9 (2/69). 
 
0.0077 
… 
 
…(*)… 
 
 
Foka 
Greek 
 
19.0 
(15/80) 
 
4.0 (4/100) 
. 
 
0.003 
 
5.5 (1.7, 17) 
 
Reznikoff-
Etievant 
 
French 10.3 
(27/260) 
4.6 
(11/240) 
.018 2.4 (1, 5) 
 
Cleary- Goldman et al 2003).(*)- The values were not calculated in the concerned references 
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The controversial results in the previous studies may be due to the racial differences in the 
study populations. It is also possible that the frequency of the mutation may be 
concentrated in a population with potential thrombotic diseases, even though the basal 
prevalence in the general population is low. This Discrepancy can be explained based on 
the genetic background variation in different populations, many affected patients do not 
have adverse effect that result from Factor V Leiden mutation ( Wramsby et al .2000 ).  
Our investigations were performed only in female patients; we suggest that more 
investigations and studies should be done including couples (parental genes). More 
investigations and studies about the fetuses will give more insight on the recurrent abortion 
health problem, especially in deciding the right type of the anticoagulants that should be 
used in the treatment of the mother (whether it should cross the placenta or not and what 
are the possible effects in both cases?). For example aspirin may be advantageous, as it 
crosses the placenta and could perhaps protect against thrombosis on the fetal side of the 
maternal fetal circulatory system. 
 
Although the Factor V Leiden mutation is one of many factors that may cause recurrent 
abortion, it is a good start to improve our knowledge about the array of factors suspected to 
play a significant role in recurrent abortion in order  to   participate  in solving  the 
recurrent abortion problem in our society.  
In our case- control study no association between Factor V Leiden and recurrent pregnancy 
loss was shown, we think that other DNA assays should be done for those women suffering 
from recurrent abortion including genes encoding the natural anticoagulants like 
antithrombin, protein C, and protein S, which results in a loss of anticoagulant function.  
Definitely , further  investigations concerning other genes related to recurrent pregnancy 
loss should be carried out similar to those done by Cyle S. Goodman et al  in which they 
found  that   a panel of thrombogenic gene mutations including factor V G1691A, factor V 
H1299R (R2), factor II prothrombin G20210A, factor XIII V34L, β-fibrinogen -455G>A, 
PAI-1 4G/5G, HPA1 a/b(L33P), MTHFR C677T, and MTHFR A1298C to identify 
individuals at high  risk for recurrent pregnancy loss (Cyle et al. 2006) . In addition to 
thrombin –receptor mutations and Vitamin K oxidation reduction complex ( VKORC). 
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Recommendations 
  
To the best of knowledge, this report is one of the first to describe the prevalence of the 
FVL mutation in women with recurrent pregnancy loss in the Palestinian population (south 
and center regions of the west bank). Data contribute to the clarification of the world wide 
distribution of the mutation in women with recurrent pregnancy loss (RPL). Since no 
association between Factor V Leiden and RPL was shown , we recommend the following: 
 
1- More studies on other DNA assays should be done for those women suffering from 
recurrent abortion including the genes encoding the natural anticoagulants antithrombin, 
protein C, and protein S, which results in a loss of anticoagulant function. Only a large 
prospective study would enable a definite conclusion regarding this relation.  
  
2- Increase public awareness about the importance of making the histopathology test for 
the abortuses in order to know the possible reasons for abortion, also the role of placental 
pathogenic mechanisms requires further evaluations. 
  
In particular, one abortion is enough for each woman to start thinking of the causes and 
how to prevent it from happening again through medical consultation. any abortion should 
be reported in her file of Medical and Obstetrical history. Women of reproductive age 
should be given correct information concerning the risk of thromboembolic complications 
related to pregnancy, oral contraception and surgery, and obstetric complications related to 
thrombophilia. 
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 IN The name of the Merciful God 
Questionaire  
 
The Relationship between Factor V Leiden Mutation 
and poor pregnancy outcomes In The West Bank  
 
 
Health Center --- ---------------- --. 
 
File number ---------- --------------.  
 
Date of Birth -----------------------. 
 
Age at marriage ---------------------. 
 
Relationship with the husband: ---------------------.  
 
Height------------- 
 
Weight ------------ 
 
The degree of education:  
 
1 - Primary         2 -secondary       3- higher than that  
 
 
Profession:  
 
1 - Housewife   2 Staff member     3- Especial work  
 
 
Age at first pregnancy (-------------).  
 
Result of first pregnancy:  
 
 1– Normal delivery  2- Caesarean delivery  3- Abortion  
 
The number of completed  pregnancies (_______)  
The number of cases of incomplete pregnancy (______).  
 
- The number of cases of non-completion in the first trimester 
of pregnancy (______).  
 
- The number of cases of non-completion of the second 
trimester of pregnancy (______).  
 
- The number of cases of non-completion of pregnancy in the 
third trimester (______). 
 
 2 
 
Put signal (X) in the right place:  
 
 
 
 
 
Question Yes NO I don’t recall 
1 Do you have diabetes? 
 
   
2 Have you suffered earlier from 
pregnancy diabetes?  
 
   
3 Do you suffer from high blood 
pressure? 
 
   
4 Have you ever suffered from pregnancy 
toxemia?  
 
 
   
5 Do you have varicose legs?  
 
 
   
6 Have you suffered earlier from clots 
in any of your legs? 
 
   
7 Do you have fiber uterus? 
 
   
8 Did you use the oral contraceptive 
pill? 
   
9 Are you a smoker? 
 
   
10 Have you ever had premature babies? 
 
   
11 Have you ever a baby born below the 
weight of 2500 grams?  
 
 
   
12 Do you already suffer the death of the 
fetus before birth?  
 
 
   
13 Do you already suffer the death of the 
fetus during childbirth?  
 
 
   
 
 
 
 
 
 
 3 
 
 
 
Has any one of your relatives (mother or sister) suffered from
  
any of the following diseases?  
 
 
 
 
Question Yes NO I don’t recall 
1 Heart infarction. 
 
   
2 Lung clots. 
 
   
3 Intravenous clots.  
 
   
4 Premature delivery. 
 
   
5 Babies born below the weight of 2500 
grams?  
 
   
6 Recurrent abortion. 
 
   
7 Placental abruption. 
 
   
8 Death of the fetus before birth?
 
   
9 Death of the fetus during childbirth? 
 
   
 
 
 
 
   Thank you for the good cooperation 
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  بسم الله الرحمن الرحيم
  "استبانه" 
  
 الضفة  /علاقة العامل الوراثي ليدن مع بعض أمراض الحمل عند النساء الفلسطينيات
  .الغربية
  
  ------------ الرقم المتسلسل---------------- رقم الملف---------------- -المرآز الصحي
  
  .-------------- العمر عند الزواج                .---------------------دتاريخ الميلا
 
  .-----------------------:صلة القرابة مع الزوج
  
  ---.-------------- الطول                        .------------------الوزن 
  
  
  :درجة التعليم
  
  من ذلك أعلى -٤ ثانوي      -٣ إعدادي                        -٢ ابتدائي                  -١
  
  
  :المهنة
  
   أعمال خاصة-٣ موظفة                 -٢ ربة بيت                            - ١    
  
  
  (.-------------)الأولالعمر عند الحمل 
  
  :الأولنتيجة الحمل 
  
   إجهاض-٣             ولادة قيصرية     -٢                      ولادة طبيعية    -١   
  
  (_____) عدد الحمول المكتملة      (   _______)عدد الحمول
     
  (.______) عدد حالات عدم اآتمال الحمل
 
  (______)عدد حالات عدم اآتمال الحمل في الثلث الاول  -
 
  (.______)عدد حالات عدم اآتمال الحمل في الثلث الثاني  -
 
 (.______)عدد حالات عدم اآتمال الحمل في الثلث الثالث  -
  
  
  
 2
 
  
  
  :في المكان المناسب ( )Xضعي إشارة 
  
  لا اذآر  لا  نعم  السؤال
  هل تعانين من السكري؟ ١
  
      
  هل عانيت من مرض سكري الحمل سابقا؟ ٢
  
      
  هل تعانين من ارتفاع ضغط الدم؟ ٣
  
      
  هل عانيت من تسمم الحمل؟ ٤
  
      
  هل تعانين من دوالي الساقين؟ ٥
  
      
  هل عانيت من تجلطات سابقة في إحدى ساقيك؟ ٦
  
      
  هل تعانين من ألياف الرحم؟ ٧
  
      
  هل استخدمت حبوب منع الحمل؟ ٨
  
      
  هل أنت مدخنة؟ ٩
  
      
  هل سبق وان ولدت ولادة مبكرة؟٠١
  
      
   غرام؟٠٠٥٢هل سبق وان ولدت أطفال دون وزن ١١
  
      
  ل الولادة؟هل سبق وان عانيت من وفاة الجنين قب٢١
  
      
  هل سبق وان عانيت من وفاة الجنين أثناء الولادة ؟٣١
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  هل يعاني احد من أقربائك من أي من الأمراض التالية؟
  
  
  لا اذآر  لا  نعم  السؤال
  تجلطات قلبية؟ ١
  
      
  تجلطات رئوية؟ ٢
  
      
  تجلطات وريدية؟ ٣
  
      
  من ولادة مبكرة؟هل عانت والدتك أو شقيقة لك  ٤
  
      
   غرام؟٠٠٥٢هل أنجبت والدتك أو شقيقة لك أطفال دون  ٥
  
      
  هل عانت والدتك أو شقيقة لك من اجهاضات متكررة؟ ٦
  
      
  هل عانت والدتك أو شقيقة لك من تسمم الحمل؟ ٧
  
      
  هل عانت والدتك أو شقيقة لك من انفصال المشيمة الحاد؟ ٨
  
      
 و شقيقة لك من وفاة الجنين قبل الولادة؟هل عانت والدتك أ ٩
  
      
هل عانت والدتك أو شقيقة لك من وفاة الجنين أثناء الولادة؟٠١
  
      
  
  
  
    وشكرا لحسن التعاون
  
  
  
  
  
  
  
  
  
  1
 
بالإجهاض المتكرر لدى النساء الفلسطينيات في مناطق الضفة " معامل لايدن " علاقة الطفرة الوراثية 
  .الغربية في فلسطين
  علا داود أبو هلال:إعداد الطالبة
  
  بروفيسور هشام درويش: إشراف
  
  ملخص
مجتمع النساء الحوامل في ال لوحظ في الآونة الأخيرة ارتفاع نسبة الاجهاضات المتكررة لدى
 تبيانالهدف الرئيسي من الدراسة هو ولأسباب غير محددة لذا آان . الفلسطيني في الضفة الغربية
من أجل تسليط الضوء على هذه المشكلة   الإجهاض المتكرر و ن العامل الخامس لايد طفرةبينالعلاقة 
  . الفلسطينيعليها في المجتمعالصحية الرئيسية ولمعرفة أفضل الحلول للقضاء 
  
 خاص بموضوع البحث وتوزيعه على النساء المشارآات بالتعاون مع ثلاث مراآز وضع استبيان تم 
ممن انطبقت عليهن شروط  نساء فقط وأربعة مئةتم اختيار و وأريحا طبية في مدن رام الله وبيت لحم 
 طبيعي، دمضغط ب  اللواتي يتمتعن من النساء٤٥  وتشملالمجموعة التجريبيةوضمت الدراسة .الدراسة
 غير  لأسبابثلاثة أو أآثر من حالات الإجهاض ) من فقدان الحمل المتكرر مرضيوتاريخ
اللواتي أنجبن على الأقل مرتين دون أي  امرأة ٠٥ شملت ي والتالمجموعة الضابطةو.(معروفة
ث لبحوا في مرآز تم إجراء البحث وقد. ةمشكلات صحية تتعلق بالحمل ويتمتعن بشكل عام بصحة جيد
عزل الحمض ب قمنا حيث (٨٠٠٢-٧٠٠٢)  في الفترة الزمنية ديسالطبية في جامعة القدس في أبو 
 )LVF( لايدن فحص طفرة العامل الخامس لتخثر الدم من عينا ت دم المشارآات ل AND أل  النووي
 الخاص (الجين)  المورثفحصل  tseT SMRAوطريقة ( RCP)التفاعل السلسلي  باستخدام طريقة
  .عامل الخامس للتخثربال
  
أما % ٨٦ التجريبية ةوقد آانت النسبة المئوية للإجهاض المتكرر بين المشارآات في المجموع
نتائج التوزيع الجيني للعامل وآانت   بنجاح فيهاالمجموعة الضابطة فقد انتهت جميع حالات الحمل
متغايرة %  ١٫٤٢)الطفرة جين  يحملن % ٨٫٧٢  التجريبية مجموعةال  في: آالأتي لخامس لايدنا
يحملن الصفة %   ٢٢  المجموعة الضابطة بينما في   (للطفرة متماثل الجينات % ٧٫٣ ،الجينات
    )423.0 eulav P(     ولا يوجد تماثل لجينات الطفرة في هذه المجموعة٠للطفرة الجينات متغايرة 
  2
 
الإجهاض المتكرر لدى النساء و" يدن معامل لا" مما يدل على انه لا توجد علاقة إحصائية قوية بين 
       .                                   الفلسطينيات
           
 بين  قليلا آانت أعلىولوحظ أنها  IMB  مؤشر آتلة الجسمباستخدام السمنةآما تم أيضا دراسة تأثير 
 eulav P() (% ٧٥ ) منها في المجموعة الضابطة(% ٦٦)النساء في المجموعة التجريبية
( % ٩٫٢١)آان أعلى قليلا في المجموعة التجريبية  sPCO آما أن معدل انتشار استخدام 341.0
 من المستخدمات % ٤١ وقد وجد أن نسبة )114.0 eulav P( ،( % ٨ ) الضابطةمجموعةال يعنها ف
 لايدن  في حين لعامل الخامسل المتغايرة لأقراص منع الحمل في المجموعة التجريبية يمتلكن الجينات
  .آن يمتلكن جينات طبيعية  الضابطةمجموعةال  المستخدمات لأقراص منع الحمل فيأن جميع
  
آلها  % ١٫١١ اتبين المشارآ )  آانت نسبة حدوثها   )DFUI(بالنسبة لوفاة الأجنة داخل الرحم أما 
نمو  وتخلف هذه الطفرةبين  ارتباط آبير لم يلاحظ آذلكو.  الخامس لايدنالوراثي للعامل طبيعية الجين
 الثلث النساء المصابات بإجهاض  توزيع جين الطفرة بينوقد آانت نسبة. RGUI داخل الرحم نالجني
أعلى منها (متماثل الجينات للطفرة % ٧٫٣+ متغاير الجينات % ٥٫٤٢%= ٣٫٨٢)الأول من الحمل 
آانت تحمل الجين  واحدةنه امرأة حيث عانت م الثلث الثاني من الحمل النساء المصابات بإجهاض بين
   .بالصورة الطبيعية
  
 " معامل لايدن " الطفرة الوراثية مما سبق نستنتج أن هذه الدراسة لم تستطع إثبات العلاقة بين 
 ضرورة عمل فحوصات مستقبلية يؤآد والاجهاضات المتكررة لدي النساء في المجتمع الفلسطيني مما 
 nibmorhtitna tnalugaocitna)مل تخثر الدم الأخرى مثل على الحمض النووي لجينات عوا
 الآباءعلى أن تشمل هذه الدراسات (الخ  ..... rotpecer nibmorht،  S nietorp ,C nietorp
متابعة الحالات التي تم استثنائها من الدراسة   مع الحرص علىلمعرفة الطرز الجينية المتوقعة للأبناء
  .الحالية  
  
على   حول هذا المرض وفراد شعبناأ العام  لدى على زيادة الوعي الصحي  الجهوديز ترآلذا نوصي ب
عمل الفحوصات اللازمة  للأجنة المجهضة لمعرفة أسباب الإجهاض المتكرر  وتسجيل حالات 
 ، بما في ذلك التشخيص  الطبيةتوفير ما يلزم من الرعاية لبدقةالإجهاض في السجل المرضي للنساء 
  .الأشخاص المصابين بهذا المرضعلاج الطبي والمواساة لتحسين نوعية حياة المبكر وال
